

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|------|
| Data Set Name | OTP.AD | Observations | 2325 |
| Member Type | DATA | Variables | 15 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:43:58 | Observation Length | 32 |
| Last Modified | 03/10/2023 17:43:58 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 2 |
| First Data Page | 1 |
| Max Obs per Page | 2039 |
| Obs in First Data Page | 1945 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_master\set\Datasets\Adults\ad.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 192KB |
| File Size (bytes) | 196608 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ad111 | Char | 1 | 11 How often have drink with alcohol |
| 6 | ad112 | Char | 1 | 12 How many drinks on typical drinking day |
| 7 | ad113 | Char | 1 | 13 How often have 6+ drinks on one occasion |
| 8 | ad114 | Char | 1 | 14 How often not able to stop drinking/past year |
| 9 | ad115 | Char | 1 | 15 How often failed to do expected in last year |
| 10 | ad116 | Char | 1 | 16 How often need drink in AM after heavy drinking |
| 11 | ad117 | Char | 1 | 17 How often felt guilt/remorse after drinking |
| 12 | ad118 | Char | 1 | 18 How often can't remember what happened night before |
| 13 | ad119 | Char | 1 | 19 Anyone injured as result of your drinking |
| 14 | ad120 | Char | 1 | 20 Anyone concerned about your drinking |
| 15 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.BG1 | Observations | 493 |
| Member Type | DATA | Variables | 371 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:43:59 | Observation Length | 1312 |
| Last Modified | 03/10/2023 17:43:59 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 106496 |
| Number of Data Set Pages | 7 |
| First Data Page | 1 |
| Max Obs per Page | 81 |
| Obs in First Data Page | 46 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\bg1.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 832KB |
| File Size (bytes) | 851968 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | bg108 | Char | 1 | 8 Relatives have liver disease |
| 6 | bg109a | Char | 1 | 9a Alcohol related liver disease |
| 7 | bg109b | Char | 1 | 9b Viral hepatitis |
| 8 | bg109c | Char | 1 | 9c Alpha-1 antitrypsin deficiency |
| 9 | bg109d | Char | 1 | 9d Wilson's disease |
| 10 | bg109e | Char | 1 | 9e Glycogen storage disease |
| 11 | bg109f | Char | 1 | 9f Iron overload |
| 12 | bg109g | Char | 1 | 9g Fatty liver disease (NAFLD, NASH) |
| 13 | bg109h | Char | 1 | 9h Type of liver disease unknown |
| 14 | bg109i | Char | 1 | 9i Other liver disease |
| 15 | bg109is | Char | 35 | 9i Specify other liver disease |
| 16 | bg110 | Char | 1 | 10 Relatives have cirrhosis |
| 17 | bg111 | Char | 1 | 11 Is cause of cirrhosis unknown |
| 18 | bg112 | Char | 1 | 12 Relatives have diabetes (Type 1 or 2) |
| 19 | bg113 | Char | 1 | 13 Relatives have obesity |
| 20 | bg114 | Char | 1 | 14 Relatives have atrophy of body fat |
| 21 | bg115 | Char | 1 | 15 Relatives have problem with cholesterol |
| 22 | bg117a | Char | 1 | 17a Symptoms for liver disease |
| 23 | bg117b | Char | 1 | 17b Evaluated for another illness |
| 24 | bg117c | Char | 1 | 17c Routine or insurance physical exam |
| 25 | bg117d | Char | 1 | 17d Blood donation |
| 26 | bg117e | Char | 1 | 17e Other |
| 27 | bg117es | Char | 35 | 17e Specify other type of evaluation |
| 28 | bg118a | Char | 1 | 18a Liver biopsy |
| 29 | bg118b | Char | 1 | 18b Imaging studies |
| 30 | bg118c | Char | 1 | 18c Elevated aminotransferases |
| 31 | bg118d | Char | 1 | 18d Other |
| 32 | bg118ds | Char | 35 | 18d Specify other test |
| 33 | bg119 | Char | 1 | 19 Liver biopsy for Database 2 |
| 34 | bg121 | Char | 1 | 21 Will patient have biopsy during screening |
| 35 | bg122 | Char | 1 | 22 Liver imaging study in past 6 mos |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 36 | bg123 | Char | 4 | 23 Patient's birthweight |
| 37 | bg124 | Char | 1 | 24 Weight pattern over past 5 years |
| 38 | bg125 | Char | 3 | 25 Current weight (lbs) |
| 39 | bg126 | Char | 3 | 26 Most ever weighed |
| 40 | bg127 | Char | 2 | 27 Age when weighed the most |
| 41 | bg128 | Char | 1 | 28 Patient age 18 or older |
| 42 | bg129 | Char | 3 | 29 Least patient has weighed |
| 43 | bg130 | Char | 2 | 30 Age when weighed the least |
| 44 | bg131 | Char | 1 | 31 Weigh more than one year ago |
| 45 | bg132 | Char | 3 | 32 lbs more that patient weighs |
| 46 | bg133 | Char | 1 | 33 Weigh less than one year ago |
| 47 | bg134 | Char | 3 | 34 lbs less that patient weighs |
| 48 | bg135 | Char | 1 | 35 Try to lose or gain weight |
| 49 | bg136 | Char | 1 | 36 Which did patient try to do |
| 50 | bg137 | Char | 1 | 37 Patient age 12 or older |
| 51 | bg138 | Char | 1 | 38 Ever smoked cigarettes |
| 52 | bg139 | Char | 1 | 39 Smoked cigarettes regularly |
| 53 | bg140 | Char | 2 | 40 Age first started smoking |
| 54 | bg141 | Char | 2 | 41 Age stopped smoking |
| 55 | bg142 | Char | 3 | 42 Number cigarettes smoked per day |
| 56 | bg143 | Char | 1 | 43 Is patient female |
| 57 | bg144 | Char | 1 | 44 Has menarche occurred |
| 58 | bg145 | Char | 2 | 45 Age at menarche |
| 59 | bg146 | Char | 1 | 46 Characterize menstrual history |
| 60 | bg147 | Char | 1 | 47 Patient post-menopausal |
| 61 | bg148 | Char | 2 | 48 Age at menopause |
| 62 | bg149a | Char | 1 | 49a Diabetes type 1 |
| 63 | bg149b | Char | 1 | 49b Diabetes type 2 |
| 64 | bg149c | Char | 1 | 49c Gestational diabetes |
| 65 | bg149d | Char | 1 | 49d Hepatitis B |
| 66 | bg149e | Char | 1 | 49e Hepatitis C |
| 67 | bg149f | Char | 1 | 49f Autoimmune hepatitis |
| 68 | bg149g | Char | 1 | 49g Autoimmune cholestatic liver disorder |
| 69 | bg149h | Char | 1 | 49h Wilson's disease |
| 70 | bg149i | Char | 1 | 49i Alpha-1-antitrypsin (A1AT) deficiency |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 71 | bg149j | Char | 1 | 49j Glycogen storage disease |
| 72 | bg149k | Char | 1 | 49k Iron overload |
| 73 | bg149l | Char | 1 | 49l Polycystic liver disease |
| 74 | bg149m | Char | 1 | 49m Drug induced liver disease |
| 75 | bg149n | Char | 1 | 49n Gilbert's syndrome |
| 76 | bg149o | Char | 1 | 49o Esophageal or gastric varices on endoscopy |
| 77 | bg149p | Char | 1 | 49p Bleeding from varices |
| 78 | bg149q | Char | 1 | 49q Other gastrointestinal bleeding |
| 79 | bg149r | Char | 1 | 49r Ascites |
| 80 | bg149s | Char | 1 | 49s Edema |
| 81 | bg149t | Char | 1 | 49t Hepatic encephalopathy |
| 82 | bg149u | Char | 1 | 49u Portal hypertension |
| 83 | bg149v | Char | 1 | 49v Hepatorenal syndrome |
| 84 | bg149w | Char | 1 | 49w Hepatopulmonary syndrome |
| 85 | bg149x | Char | 1 | 49x Short bowel syndrome |
| 86 | bg149y | Char | 1 | 49y Hemophilia |
| 87 | bg149z | Char | 1 | 49z HIV positive |
| 88 | bg149aa | Char | 1 | 49aa Systemic autoimmune disorder |
| 89 | bg149ab | Char | 1 | 49ab Endocrine disease |
| 90 | bg149ac | Char | 1 | 49ac Hepatocellular carcinoma |
| 91 | bg149ad | Char | 1 | 49ad Other malignancy |
| 92 | bg149ae | Char | 1 | 49ae Peripheral neuropathy |
| 93 | bg149af | Char | 1 | 49af Seizure disorder or epilepsy |
| 94 | bg149ag | Char | 1 | 49ag Drug allergies |
| 95 | bg149ah | Char | 1 | 49ah Hypothyroidism |
| 96 | bg149ai | Char | 1 | 49ai Hypertension |
| 97 | bg149aj | Char | 1 | 49aj Cerebrovascular disease |
| 98 | bg149ak | Char | 1 | 49ak Dysbetalipoproteinemia |
| 99 | bg149al | Char | 1 | 49al Chronic cholestasis |
| 100 | bg149am | Char | 1 | 49am Hyperlipidemia |
| 101 | bg149an | Char | 1 | 49an Pancreatitis |
| 102 | bg149ao | Char | 1 | 49ao Cholelithiasis |
| 103 | bg149ap | Char | 1 | 49ap Coronary artery disease |
| 104 | bg149aq | Char | 1 | 49aq Elevated uric acid |
| 105 | bg149ar | Char | 1 | 49ar Kidney disease |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 106 | bg149as | Char | 1 | 49as Polycystic ovary syndrome |
| 107 | bg149at | Char | 1 | 49at Sleep apnea |
| 108 | bg149au | Char | 1 | 49au Dermatologic disorders |
| 109 | bg149av | Char | 1 | 49av Myopathy |
| 110 | bg149aw | Char | 1 | 49aw Myositis |
| 111 | bg149ax | Char | 1 | 49ax Major depression |
| 112 | bg149ay | Char | 1 | 49ay Schizophrenia |
| 113 | bg149az | Char | 1 | 49az Bipolar disorder |
| 114 | bg149ba | Char | 1 | 49ba Obsessive compulsive disorder |
| 115 | bg149bb | Char | 1 | 49bb Severe anxiety or personality disorder |
| 116 | bg149bc | Char | 1 | 49bc None of the above |
| 117 | bg150a | Char | 1 | 50a Stapling of the stomach |
| 118 | bg150b | Char | 1 | 50b Jejunioleal bypass |
| 119 | bg150c | Char | 1 | 50c Biliopancreatic diversion |
| 120 | bg150d | Char | 1 | 50d Other GI or bariatric surgery |
| 121 | bg150ds | Char | 35 | 50d Specify other surgery |
| 122 | bg150e | Char | 1 | 50e None of the above |
| 123 | bg151a | Char | 1 | 51a Liver transplant ever |
| 124 | bg151b | Char | 1 | 51b Organ/limb/bone marrow transplant ever |
| 125 | bg152 | Char | 1 | 52 Received TPN 6 months prior to liver bx |
| 126 | bg153 | Char | 1 | 53 Undergoing evaluation for bariatric surgery |
| 127 | bg154 | Char | 1 | 54 Symptoms of sleep apnea |
| 128 | bg155 | Char | 1 | 55 Antidiabetic medications |
| 129 | bg155a | Char | 1 | 55a Acarbose |
| 130 | bg155b | Char | 1 | 55b Acetohexamide |
| 131 | bg155c | Char | 1 | 55c Chlorpropamide |
| 132 | bg155d | Char | 1 | 55d Glimepiride |
| 133 | bg155e | Char | 1 | 55e Glipizide |
| 134 | bg155f | Char | 1 | 55f Glyburide |
| 135 | bg155g | Char | 1 | 55g Insulin |
| 136 | bg155h | Char | 1 | 55h Metformin |
| 137 | bg155i | Char | 1 | 55i Miglitol |
| 138 | bg155j | Char | 1 | 55j Nateglinide |
| 139 | bg155k | Char | 1 | 55k Pioglitazone |
| 140 | bg155l | Char | 1 | 55l Repaglinide |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 141 | bg155m | Char | 1 | 55m Rosiglitazone |
| 142 | bg155n | Char | 1 | 55n Tolazamide |
| 143 | bg155o | Char | 1 | 55o Tolbutamide |
| 144 | bg155p | Char | 1 | 55p Other antidiabetic drug |
| 145 | bg155ps | Char | 35 | 55p Specify other antidiabetic drug |
| 146 | bg156 | Char | 1 | 56 Alcohol abuse medications |
| 147 | bg156a | Char | 1 | 56a Chlordiazepoxide |
| 148 | bg156b | Char | 1 | 56b Clorazepate dipotassium |
| 149 | bg156c | Char | 1 | 56c Diazepam |
| 150 | bg156d | Char | 1 | 56d Disulfiram |
| 151 | bg156e | Char | 1 | 56e Hydroxyzine pamoate |
| 152 | bg156f | Char | 1 | 56f Naltrexone hydrochloride |
| 153 | bg156g | Char | 1 | 56g Other alcohol abuse drug |
| 154 | bg157 | Char | 1 | 57 Antihyperlipidemic medications |
| 155 | bg157a | Char | 1 | 57a Atorvastatin |
| 156 | bg157b | Char | 1 | 57b Colestipol hydrochloride |
| 157 | bg157c | Char | 1 | 57c Clofibrate |
| 158 | bg157d | Char | 1 | 57d Gemfibrozil |
| 159 | bg157e | Char | 1 | 57e Fenofibrate |
| 160 | bg157f | Char | 1 | 57f Fluvastatine sodium |
| 161 | bg157g | Char | 1 | 57g Lovastatin |
| 162 | bg157h | Char | 1 | 57h Nicotinic acid |
| 163 | bg157i | Char | 1 | 57i Pravastatin sodium |
| 164 | bg157j | Char | 1 | 57j Rosuvastatin |
| 165 | bg157k | Char | 1 | 57k Simvastatin |
| 166 | bg157l | Char | 1 | 57l Other antihyperlipidemic drug |
| 167 | bg157ls | Char | 35 | 57l Specify other antihyperlipidemic drug |
| 168 | bg158 | Char | 1 | 58 Antiobesity medications |
| 169 | bg158a | Char | 1 | 58a Dexfenfluramine hydrochloride |
| 170 | bg158b | Char | 1 | 58b Fenfluramine hydrochloride |
| 171 | bg158c | Char | 1 | 58c Methamphetamine hydrochloride |
| 172 | bg158d | Char | 1 | 58d Orlistat |
| 173 | bg158e | Char | 1 | 58e Phendimetrazine tartrate |
| 174 | bg158f | Char | 1 | 58f Phentermine hydrochloride |
| 175 | bg158g | Char | 1 | 58g Sibutramine hydrochloride monohydrate |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 176 | bg158h | Char | 1 | 58h Other antiobesity drug |
| 177 | bg158hs | Char | 35 | 58h Specify other antiobesity drug |
| 178 | bg159 | Char | 1 | 59 NSAID or aspirin medications |
| 179 | bg159a | Char | 1 | 59a Acetaminophen |
| 180 | bg159b | Char | 1 | 59b Aspirin - 325 mg |
| 181 | bg159c | Char | 1 | 59c Aspirin - 81 mg |
| 182 | bg159d | Char | 1 | 59d Celecoxib |
| 183 | bg159e | Char | 1 | 59e Ibuprofen |
| 184 | bg159f | Char | 1 | 59f Indomethacin |
| 185 | bg159g | Char | 1 | 59g Naproxen |
| 186 | bg159h | Char | 1 | 59h Rofecoxib |
| 187 | bg159i | Char | 1 | 59i Other NSAID or aspirin drug |
| 188 | bg159is | Char | 35 | 59i Specify other NSAID or aspirin drug |
| 189 | bg159j | Char | 1 | 59j Other NSAID or aspirin drug |
| 190 | bg159js | Char | 35 | 59j Specify other NSAID or aspirin drug |
| 191 | bg160 | Char | 1 | 60 Opiates containing acetaminophen |
| 192 | bg160a | Char | 1 | 60a Darvocet |
| 193 | bg160b | Char | 1 | 60b Esgic - Plus |
| 194 | bg160c | Char | 1 | 60c Fioricet |
| 195 | bg160d | Char | 1 | 60d Lorcet |
| 196 | bg160e | Char | 1 | 60e Lortab |
| 197 | bg160f | Char | 1 | 60f Norco |
| 198 | bg160g | Char | 1 | 60g Percocet |
| 199 | bg160h | Char | 1 | 60h Talacen |
| 200 | bg160i | Char | 1 | 60i Tylenol #3 |
| 201 | bg160j | Char | 1 | 60j Tylenol #4 |
| 202 | bg160k | Char | 1 | 60k Tylox |
| 203 | bg160l | Char | 1 | 60l Vicodin |
| 204 | bg160m | Char | 1 | 60m Wygesic |
| 205 | bg160n | Char | 1 | 60n Other opiate w/acetaminophen |
| 206 | bg160ns | Char | 35 | 60n Specify other opiate w/acetaminophen |
| 207 | bg161 | Char | 1 | 61 Histamine H2 receptor antagonists |
| 208 | bg161a | Char | 1 | 61a Cimetidine |
| 209 | bg161b | Char | 1 | 61b Esomeprazole magnesium |
| 210 | bg161c | Char | 1 | 61c Famotidine |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 211 | bg161d | Char | 1 | 61d Lansoprazole |
| 212 | bg161e | Char | 1 | 61e Nizatidine |
| 213 | bg161f | Char | 1 | 61f Omeprazole |
| 214 | bg161g | Char | 1 | 61g Ranitidine |
| 215 | bg161h | Char | 1 | 61h Ranitidine bismuth citrate |
| 216 | bg161i | Char | 1 | 61i Antacids |
| 217 | bg161is | Char | 35 | 61i Specify antacids |
| 218 | bg161j | Char | 1 | 61j Other |
| 219 | bg161js | Char | 35 | 61j Specify other |
| 220 | bg162 | Char | 1 | 62 Anticoagulant/antiplatelet medications |
| 221 | bg162a | Char | 1 | 62a Clopidogrel |
| 222 | bg162b | Char | 1 | 62b Dipyridamole |
| 223 | bg162c | Char | 1 | 62c Heparin |
| 224 | bg162d | Char | 1 | 62d Ticlopidine |
| 225 | bg162e | Char | 1 | 62e Warfarin |
| 226 | bg162f | Char | 1 | 62f Other anticoagulant |
| 227 | bg162fs | Char | 35 | 62f Specify other anticoagulant |
| 228 | bg163 | Char | 1 | 63 Systemic corticosteroids |
| 229 | bg163a | Char | 1 | 63a Betamethasone sodium |
| 230 | bg163b | Char | 1 | 63b Cortisol |
| 231 | bg163c | Char | 1 | 63c Cortisone |
| 232 | bg163d | Char | 1 | 63d Dexamethasone |
| 233 | bg163e | Char | 1 | 63e Hydrocortisone |
| 234 | bg163f | Char | 1 | 63f Methylprednisolone |
| 235 | bg163g | Char | 1 | 63g Prednisolone |
| 236 | bg163h | Char | 1 | 63h Prednisone |
| 237 | bg163i | Char | 1 | 63i Triamcinolone |
| 238 | bg163j | Char | 1 | 63j Other systemic corticosteroids |
| 239 | bg163js | Char | 35 | 63j Specify other systemic corticosteroids |
| 240 | bg164 | Char | 1 | 64 Cardiovascular/antihypertensive medications |
| 241 | bg164a | Char | 1 | 64a Amiodarone |
| 242 | bg164b | Char | 1 | 64b Amlodipine besylate |
| 243 | bg164c | Char | 1 | 64c Atenolol |
| 244 | bg164d | Char | 1 | 64d Benazepril |
| 245 | bg164e | Char | 1 | 64e Captopril |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 246 | bg164f | Char | 1 | 64f Clonidine |
| 247 | bg164g | Char | 1 | 64g Digoxin |
| 248 | bg164h | Char | 1 | 64h Diltiazem |
| 249 | bg164i | Char | 1 | 64i Doxazosin |
| 250 | bg164j | Char | 1 | 64j Enalapril |
| 251 | bg164k | Char | 1 | 64k Felodipine |
| 252 | bg164l | Char | 1 | 64l Furosemide |
| 253 | bg164m | Char | 1 | 64m Hydrochlorothiazide |
| 254 | bg164n | Char | 1 | 64n Hydrochlorothiazide + triamterene |
| 255 | bg164o | Char | 1 | 64o Lisinopril |
| 256 | bg164p | Char | 1 | 64p Losartan potassium |
| 257 | bg164q | Char | 1 | 64q Losartan potassium with hydrochlorothiazide |
| 258 | bg164r | Char | 1 | 64r Metoprolol |
| 259 | bg164s | Char | 1 | 64s Nifedipine |
| 260 | bg164t | Char | 1 | 64t Perhexiline maleate |
| 261 | bg164u | Char | 1 | 64u Propranolol |
| 262 | bg164v | Char | 1 | 64v Quinapril |
| 263 | bg164w | Char | 1 | 64w Terazosin |
| 264 | bg164x | Char | 1 | 64x Timolol maleate |
| 265 | bg164y | Char | 1 | 64y Valsartan |
| 266 | bg164z | Char | 1 | 64z Verapamil |
| 267 | bg164aa | Char | 1 | 64aa Other cardiovascular/antihypertensive |
| 268 | bg164aas | Char | 35 | 64aa Specify other cardiovascular/antihypertensive |
| 269 | bg164ab | Char | 1 | 64ab Other cardiovascular/antihypertensive |
| 270 | bg164abs | Char | 35 | 64ab Specify other cardiovascular/antihypertensive |
| 271 | bg165 | Char | 1 | 65 Estrogen, progestin, HRT medications |
| 272 | bg165a | Char | 1 | 65a Conjugated estrogen |
| 273 | bg165b | Char | 1 | 65b Diethylstilbestrol and methyltestosterone |
| 274 | bg165c | Char | 1 | 65c Esterified estrogen |
| 275 | bg165d | Char | 1 | 65d Estradiol |
| 276 | bg165e | Char | 1 | 65e Ethinyl estradiol |
| 277 | bg165f | Char | 1 | 65f Fluoxymesterone |
| 278 | bg165g | Char | 1 | 65g Levonorgestrel |
| 279 | bg165h | Char | 1 | 65h Medroxyprogesterone |
| 280 | bg165i | Char | 1 | 65i Megestrol |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 281 | bg165j | Char | 1 | 65j Methyltestosterone |
| 282 | bg165k | Char | 1 | 65k Nandrolone |
| 283 | bg165l | Char | 1 | 65l Norethindrone |
| 284 | bg165m | Char | 1 | 65m Norgestrel |
| 285 | bg165n | Char | 1 | 65n Oral contraceptives |
| 286 | bg165o | Char | 1 | 65o Oxandrolone |
| 287 | bg165p | Char | 1 | 65p Oxymetholone |
| 288 | bg165q | Char | 1 | 65q Progesterone |
| 289 | bg165r | Char | 1 | 65r Raloxifene |
| 290 | bg165s | Char | 1 | 65s Tamoxifen |
| 291 | bg165t | Char | 1 | 65t Other hormone replacements |
| 292 | bg165ts | Char | 35 | 65t Specify other hormone replacements |
| 293 | bg165u | Char | 1 | 65u Other hormone replacements |
| 294 | bg165us | Char | 35 | 65u Specify other hormone replacements |
| 295 | bg166 | Char | 1 | 66 Allergy or asthma medications |
| 296 | bg166a | Char | 1 | 66a Beclomethasone dipropionate |
| 297 | bg166b | Char | 1 | 66b Budesonide |
| 298 | bg166c | Char | 1 | 66c Fluticasone propionate |
| 299 | bg166d | Char | 1 | 66d Loratadine |
| 300 | bg166e | Char | 1 | 66e Mometasone furoate |
| 301 | bg166f | Char | 1 | 66f Triamcinolone acetoneide |
| 302 | bg166g | Char | 1 | 66g Other asthma medications |
| 303 | bg166gs | Char | 35 | 66g Specify other asthma medications |
| 304 | bg166h | Char | 1 | 66h Other asthma medications |
| 305 | bg166hs | Char | 35 | 66h Specify other asthma medications |
| 306 | bg167 | Char | 1 | 67 Taken a multivitamin in past 6 months |
| 307 | bg168 | Char | 1 | 68 Taken other vitamins in past 6 months |
| 308 | bg169a | Char | 1 | 69a Vitamin B |
| 309 | bg169b | Char | 1 | 69b Vitamin C |
| 310 | bg169c | Char | 1 | 69c Vitamin D |
| 311 | bg169d | Char | 1 | 69d Vitamin E |
| 312 | bg169e | Char | 1 | 69e Other vitamins |
| 313 | bg169es | Char | 35 | 69e Specify other vitamins |
| 314 | bg170 | Char | 1 | 70 Supplements in past 3 months |
| 315 | bg170a | Char | 1 | 70a Alpha-lipoic acid |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 316 | bg170b | Char | 1 | 70b Alpha-tocopherol |
| 317 | bg170c | Char | 1 | 70c Beta-carotene |
| 318 | bg170d | Char | 1 | 70d Betaine |
| 319 | bg170e | Char | 1 | 70e Calcium |
| 320 | bg170f | Char | 1 | 70f Carnitine |
| 321 | bg170g | Char | 1 | 70g Chondroitin |
| 322 | bg170h | Char | 1 | 70h Choline + methionine...+ pyridoxine |
| 323 | bg170i | Char | 1 | 70i Cod liver oil |
| 324 | bg170j | Char | 1 | 70j Coenzyme Q |
| 325 | bg170k | Char | 1 | 70k Dichloroacetate |
| 326 | bg170l | Char | 1 | 70l Echinacea |
| 327 | bg170m | Char | 1 | 70m Fish oil |
| 328 | bg170n | Char | 1 | 70n Flax seed oil |
| 329 | bg170o | Char | 1 | 70o Garlic |
| 330 | bg170p | Char | 1 | 70p Ginkgo biloba |
| 331 | bg170q | Char | 1 | 70q Glucosamine |
| 332 | bg170r | Char | 1 | 70r Lecithin |
| 333 | bg170s | Char | 1 | 70s Magnesium |
| 334 | bg170t | Char | 1 | 70t Milk thistle |
| 335 | bg170u | Char | 1 | 70u N-acetyl-cysteine |
| 336 | bg170v | Char | 1 | 70v Potassium |
| 337 | bg170w | Char | 1 | 70w S-adenylmethionine |
| 338 | bg170x | Char | 1 | 70x Saw palmetto |
| 339 | bg170y | Char | 1 | 70y Selenium |
| 340 | bg170z | Char | 1 | 70z St John's Wort |
| 341 | bg170aa | Char | 1 | 70aa Taurine |
| 342 | bg170ab | Char | 1 | 70ab Zinc picolinate |
| 343 | bg170ac | Char | 1 | 70ac Other supplements |
| 344 | bg170acs | Char | 35 | 70ac Specify other supplements |
| 345 | bg170ad | Char | 1 | 70ad Other supplements |
| 346 | bg170ads | Char | 35 | 70ad Specify other supplements |
| 347 | bg171 | Char | 1 | 71 Other medications/supplements |
| 348 | bg171a | Char | 1 | 71a Demeclocycline |
| 349 | bg171b | Char | 1 | 71b Divalproex |
| 350 | bg171c | Char | 1 | 71c Doxycycline |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 351 | bg171d | Char | 1 | 71d Isotretinoin |
| 352 | bg171e | Char | 1 | 71e Levothyroxine |
| 353 | bg171f | Char | 1 | 71f Liothyronine |
| 354 | bg171g | Char | 1 | 71g Methotrexate |
| 355 | bg171h | Char | 1 | 71h Minocycline |
| 356 | bg171i | Char | 1 | 71i Oxytetracycline |
| 357 | bg171j | Char | 1 | 71j Penicillamine |
| 358 | bg171k | Char | 1 | 71k Tetracycline |
| 359 | bg171l | Char | 1 | 71l Trientine hydrochloride |
| 360 | bg171m | Char | 1 | 71m Ursodeoxycholic acid |
| 361 | bg171n | Char | 1 | 71n Valproate sodium |
| 362 | bg171o | Char | 1 | 71o Valproic acid |
| 363 | bg171p | Char | 1 | 71p Other |
| 364 | bg171ps | Char | 35 | 71p Specify other |
| 365 | bg171q | Char | 1 | 71q Other |
| 366 | bg171qs | Char | 35 | 71q Specify other |
| 367 | bg171r | Char | 1 | 71r Other |
| 368 | bg171rs | Char | 35 | 71r Specify other |
| 369 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 370 | bg116 | Num | 8 | 16 Diagnosis date: fatty liver dx or cirrhosis (days since enrollment) |
| 371 | bg120 | Num | 8 | 20 Date of liver biopsy (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.BG2 | Observations | 1832 |
| Member Type | DATA | Variables | 373 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:01 | Observation Length | 1344 |
| Last Modified | 03/10/2023 17:44:01 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 110592 |
| Number of Data Set Pages | 23 |
| First Data Page | 1 |
| Max Obs per Page | 82 |
| Obs in First Data Page | 48 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\bg2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 3MB |
| File Size (bytes) | 2654208 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | bg208 | Char | 1 | 8 Relatives have liver disease |
| 6 | bg208a | Char | 1 | 8a Relatives died of liver disease |
| 7 | bg209a | Char | 1 | 9a Alcohol related liver disease |
| 8 | bg209b | Char | 1 | 9b Viral hepatitis |
| 9 | bg209c | Char | 1 | 9c Alpha-1 antitrypsin deficiency |
| 10 | bg209d | Char | 1 | 9d Wilson's disease |
| 11 | bg209e | Char | 1 | 9e Glycogen storage disease |
| 12 | bg209f | Char | 1 | 9f Iron overload |
| 13 | bg209g | Char | 1 | 9g Fatty liver disease (NAFLD, NASH) |
| 14 | bg209h | Char | 1 | 9h Type of liver disease unknown |
| 15 | bg209i | Char | 1 | 9i Other liver disease |
| 16 | bg209is | Char | 35 | 9i Specify other liver disease |
| 17 | bg210 | Char | 1 | 10 Relatives have cirrhosis |
| 18 | bg211 | Char | 1 | 11 Is cause of cirrhosis unknown |
| 19 | bg212 | Char | 1 | 12 Relatives have diabetes (Type 1 or 2) |
| 20 | bg213 | Char | 1 | 13 Relatives have obesity |
| 21 | bg214 | Char | 1 | 14 Relatives have atrophy of body fat |
| 22 | bg215 | Char | 1 | 15 Relatives have problem with cholesterol |
| 23 | bg217a | Char | 1 | 17a Symptoms for liver disease |
| 24 | bg217b | Char | 1 | 17b Evaluated for another illness |
| 25 | bg217c | Char | 1 | 17c Routine or insurance physical exam |
| 26 | bg217d | Char | 1 | 17d Blood donation |
| 27 | bg217e | Char | 1 | 17e Other |
| 28 | bg217es | Char | 35 | 17e Specify other type of evaluation |
| 29 | bg218a | Char | 1 | 18a Liver biopsy |
| 30 | bg218b | Char | 1 | 18b Imaging studies |
| 31 | bg218c | Char | 1 | 18c Elevated aminotransferases |
| 32 | bg218d | Char | 1 | 18d Other |
| 33 | bg218ds | Char | 35 | 18d Specify other test |
| 34 | bg219 | Char | 1 | 19 Liver biopsy for Database 2 |
| 35 | bg221 | Char | 1 | 21 Will patient have biopsy during screening |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 36 | bg222 | Char | 1 | 22 Liver imaging study in past 6 mos |
| 37 | bg223 | Char | 4 | 23 Patient's birthweight |
| 38 | bg224 | Char | 1 | 24 Weight pattern over past 5 years |
| 39 | bg225 | Char | 3 | 25 Current weight (lbs) |
| 40 | bg226 | Char | 3 | 26 Most ever weighed |
| 41 | bg227 | Char | 2 | 27 Age when weighed the most |
| 42 | bg228 | Char | 1 | 28 Patient age 18 or older |
| 43 | bg229 | Char | 3 | 29 Least patient has weighed |
| 44 | bg230 | Char | 2 | 30 Age when weighed the least |
| 45 | bg231 | Char | 1 | 31 Weigh more than one year ago |
| 46 | bg232 | Char | 3 | 32 lbs more that patient weighs |
| 47 | bg233 | Char | 1 | 33 Weigh less than one year ago |
| 48 | bg234 | Char | 3 | 34 lbs less that patient weighs |
| 49 | bg235 | Char | 1 | 35 Try to lose or gain weight |
| 50 | bg236 | Char | 1 | 36 Which did patient try to do |
| 51 | bg237 | Char | 1 | 37 Patient age 12 or older |
| 52 | bg238 | Char | 1 | 38 Ever smoked cigarettes |
| 53 | bg239 | Char | 1 | 39 Smoked cigarettes regularly |
| 54 | bg240 | Char | 2 | 40 Age first started smoking |
| 55 | bg241 | Char | 2 | 41 Age stopped smoking |
| 56 | bg242 | Char | 3 | 42 Number cigarettes smoked per day |
| 57 | bg243 | Char | 1 | 43 Is patient female |
| 58 | bg244 | Char | 1 | 44 Has menarche occurred |
| 59 | bg245 | Char | 2 | 45 Age at menarche |
| 60 | bg246 | Char | 1 | 46 Characterize menstrual history |
| 61 | bg247 | Char | 1 | 47 Patient post-menopausal |
| 62 | bg248 | Char | 2 | 48 Age at menopause |
| 63 | bg249a | Char | 1 | 49a Diabetes type 1 |
| 64 | bg249b | Char | 1 | 49b Diabetes type 2 |
| 65 | bg249c | Char | 1 | 49c Gestational diabetes |
| 66 | bg249d | Char | 1 | 49d Hepatitis B |
| 67 | bg249e | Char | 1 | 49e Hepatitis C |
| 68 | bg249f | Char | 1 | 49f Autoimmune hepatitis |
| 69 | bg249g | Char | 1 | 49g Autoimmune cholestatic liver disorder |
| 70 | bg249h | Char | 1 | 49h Wilson's disease |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 71 | bg249i | Char | 1 | 49i Alpha-1-antitrypsin (A1AT) deficiency |
| 72 | bg249j | Char | 1 | 49j Glycogen storage disease |
| 73 | bg249k | Char | 1 | 49k Iron overload |
| 74 | bg249l | Char | 1 | 49l Polycystic liver disease |
| 75 | bg249m | Char | 1 | 49m Drug induced liver disease |
| 76 | bg249n | Char | 1 | 49n Gilbert's syndrome |
| 77 | bg249o | Char | 1 | 49o Esophageal or gastric varices on endoscopy |
| 78 | bg249p | Char | 1 | 49p Bleeding from varices |
| 79 | bg249q | Char | 1 | 49q Other gastrointestinal bleeding |
| 80 | bg249r | Char | 1 | 49r Ascites |
| 81 | bg249s | Char | 1 | 49s Edema |
| 82 | bg249t | Char | 1 | 49t Hepatic encephalopathy |
| 83 | bg249u | Char | 1 | 49u Portal hypertension |
| 84 | bg249v | Char | 1 | 49v Hepatorenal syndrome |
| 85 | bg249w | Char | 1 | 49w Hepatopulmonary syndrome |
| 86 | bg249x | Char | 1 | 49x Short bowel syndrome |
| 87 | bg249y | Char | 1 | 49y Hemophilia |
| 88 | bg249z | Char | 1 | 49z HIV positive |
| 89 | bg249aa | Char | 1 | 49aa Systemic autoimmune disorder |
| 90 | bg249ab | Char | 1 | 49ab Endocrine disease |
| 91 | bg249ac | Char | 1 | 49ac Hepatocellular carcinoma |
| 92 | bg249ad | Char | 1 | 49ad Other malignancy |
| 93 | bg249ae | Char | 1 | 49ae Peripheral neuropathy |
| 94 | bg249af | Char | 1 | 49af Seizure disorder or epilepsy |
| 95 | bg249ag | Char | 1 | 49ag Drug allergies |
| 96 | bg249ah | Char | 1 | 49ah Hypothyroidism |
| 97 | bg249ai | Char | 1 | 49ai Hypertension |
| 98 | bg249aj | Char | 1 | 49aj Cerebrovascular disease |
| 99 | bg249ak | Char | 1 | 49ak Dysbetalipoproteinemia |
| 100 | bg249al | Char | 1 | 49al Chronic cholestasis |
| 101 | bg249am | Char | 1 | 49am Hyperlipidemia |
| 102 | bg249an | Char | 1 | 49an Pancreatitis |
| 103 | bg249ao | Char | 1 | 49ao Cholelithiasis |
| 104 | bg249ap | Char | 1 | 49ap Coronary artery disease |
| 105 | bg249aq | Char | 1 | 49aq Elevated uric acid |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 106 | bg249ar | Char | 1 | 49ar Kidney disease |
| 107 | bg249as | Char | 1 | 49as Polycystic ovary syndrome |
| 108 | bg249at | Char | 1 | 49at Sleep apnea |
| 109 | bg249au | Char | 1 | 49au Dermatologic disorders |
| 110 | bg249av | Char | 1 | 49av Myopathy |
| 111 | bg249aw | Char | 1 | 49aw Myositis |
| 112 | bg249ax | Char | 1 | 49ax Major depression |
| 113 | bg249ay | Char | 1 | 49ay Schizophrenia |
| 114 | bg249az | Char | 1 | 49az Bipolar disorder |
| 115 | bg249ba | Char | 1 | 49ba Obsessive compulsive disorder |
| 116 | bg249bb | Char | 1 | 49bb Severe anxiety or personality disorder |
| 117 | bg249bc | Char | 1 | 49bc None of the above |
| 118 | bg250a | Char | 1 | 50a Stapling of the stomach |
| 119 | bg250b | Char | 1 | 50b Jejunioileal bypass |
| 120 | bg250c | Char | 1 | 50c Biliopancreatic diversion |
| 121 | bg250d | Char | 1 | 50d Other GI or bariatric surgery |
| 122 | bg250ds | Char | 35 | 50d Specify other surgery |
| 123 | bg250e | Char | 1 | 50e None of the above |
| 124 | bg251a | Char | 1 | 51a Liver transplant ever |
| 125 | bg251b | Char | 1 | 51b Organ/limb/bone marrow transplant ever |
| 126 | bg252 | Char | 1 | 52 Received TPN 6 months prior to liver bx |
| 127 | bg253 | Char | 1 | 53 Undergoing evaluation for bariatric surgery |
| 128 | bg254 | Char | 1 | 54 Symptoms of sleep apnea |
| 129 | bg255 | Char | 1 | 55 Antidiabetic medications |
| 130 | bg255a | Char | 1 | 55a Acarbose |
| 131 | bg255b | Char | 1 | 55b Acetohexamide |
| 132 | bg255c | Char | 1 | 55c Chlorpropamide |
| 133 | bg255d | Char | 1 | 55d Glimepiride |
| 134 | bg255e | Char | 1 | 55e Glipizide |
| 135 | bg255f | Char | 1 | 55f Glyburide |
| 136 | bg255g | Char | 1 | 55g Insulin |
| 137 | bg255h | Char | 1 | 55h Metformin |
| 138 | bg255i | Char | 1 | 55i Miglitol |
| 139 | bg255j | Char | 1 | 55j Nateglinide |
| 140 | bg255k | Char | 1 | 55k Pioglitazone |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 141 | bg255l | Char | 1 | 55l Repaglinide |
| 142 | bg255m | Char | 1 | 55m Rosiglitazone |
| 143 | bg255n | Char | 1 | 55n Tolazamide |
| 144 | bg255o | Char | 1 | 55o Tolbutamide |
| 145 | bg255p | Char | 1 | 55p Other antidiabetic drug |
| 146 | bg255ps | Char | 35 | 55p Specify other antidiabetic drug |
| 147 | bg256 | Char | 1 | 56 Alcohol abuse medications |
| 148 | bg256a | Char | 1 | 56a Chlordiazepoxide |
| 149 | bg256b | Char | 1 | 56b Clorazepate dipotassium |
| 150 | bg256c | Char | 1 | 56c Diazepam |
| 151 | bg256d | Char | 1 | 56d Disulfiram |
| 152 | bg256e | Char | 1 | 56e Hydroxyzine pamoate |
| 153 | bg256f | Char | 1 | 56f Naltrexone hydrochloride |
| 154 | bg256g | Char | 1 | 56g Other alcohol abuse drug |
| 155 | bg256gs | Char | 35 | 56g Specify other alcohol abuse drug |
| 156 | bg257 | Char | 1 | 57 Antihyperlipidemic medications |
| 157 | bg257a | Char | 1 | 57a Atorvastatin |
| 158 | bg257b | Char | 1 | 57b Colestipol hydrochloride |
| 159 | bg257c | Char | 1 | 57c Clofibrate |
| 160 | bg257d | Char | 1 | 57d Gemfibrozil |
| 161 | bg257e | Char | 1 | 57e Fenofibrate |
| 162 | bg257f | Char | 1 | 57f Fluvastatine sodium |
| 163 | bg257g | Char | 1 | 57g Lovastatin |
| 164 | bg257h | Char | 1 | 57h Nicotinic acid |
| 165 | bg257i | Char | 1 | 57i Pravastatin sodium |
| 166 | bg257j | Char | 1 | 57j Rosuvastatin |
| 167 | bg257k | Char | 1 | 57k Simvastatin |
| 168 | bg257l | Char | 1 | 57l Other antihyperlipidemic drug |
| 169 | bg257ls | Char | 35 | 57l Specify other antihyperlipidemic drug |
| 170 | bg258 | Char | 1 | 58 Antiobesity medications |
| 171 | bg258a | Char | 1 | 58a Dexfenfluramine hydrochloride |
| 172 | bg258b | Char | 1 | 58b Fenfluramine hydrochloride |
| 173 | bg258c | Char | 1 | 58c Methamphetamine hydrochloride |
| 174 | bg258d | Char | 1 | 58d Orlistat |
| 175 | bg258e | Char | 1 | 58e Phendimetrazine tartrate |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 176 | bg258f | Char | 1 | 58f Phentermine hydrochloride |
| 177 | bg258g | Char | 1 | 58g Sibutramine hydrochloride monohydrate |
| 178 | bg258h | Char | 1 | 58h Other antiobesity drug |
| 179 | bg258hs | Char | 35 | 58h Specify other antiobesity drug |
| 180 | bg259 | Char | 1 | 59 NSAID or aspirin medications |
| 181 | bg259a | Char | 1 | 59a Acetaminophen |
| 182 | bg259b | Char | 1 | 59b Aspirin - 325 mg |
| 183 | bg259c | Char | 1 | 59c Aspirin - 81 mg |
| 184 | bg259d | Char | 1 | 59d Celecoxib |
| 185 | bg259e | Char | 1 | 59e Ibuprofen |
| 186 | bg259f | Char | 1 | 59f Indomethacin |
| 187 | bg259g | Char | 1 | 59g Naproxen |
| 188 | bg259h | Char | 1 | 59h Rofecoxib |
| 189 | bg259i | Char | 1 | 59i Other NSAID or aspirin drug |
| 190 | bg259is | Char | 35 | 59i Specify other NSAID or aspirin drug |
| 191 | bg259j | Char | 1 | 59j Other NSAID or aspirin drug |
| 192 | bg259js | Char | 35 | 59j Specify other NSAID or aspirin drug |
| 193 | bg260 | Char | 1 | 60 Opiates containing acetaminophen |
| 194 | bg260a | Char | 1 | 60a Darvocet |
| 195 | bg260b | Char | 1 | 60b Esgic - Plus |
| 196 | bg260c | Char | 1 | 60c Fioricet |
| 197 | bg260d | Char | 1 | 60d Lorcet |
| 198 | bg260e | Char | 1 | 60e Lortab |
| 199 | bg260f | Char | 1 | 60f Norco |
| 200 | bg260g | Char | 1 | 60g Percocet |
| 201 | bg260h | Char | 1 | 60h Talacen |
| 202 | bg260i | Char | 1 | 60i Tylenol #3 |
| 203 | bg260j | Char | 1 | 60j Tylenol #4 |
| 204 | bg260k | Char | 1 | 60k Tylox |
| 205 | bg260l | Char | 1 | 60l Vicodin |
| 206 | bg260m | Char | 1 | 60m Wygesic |
| 207 | bg260n | Char | 1 | 60n Other opiate w/acetaminophen |
| 208 | bg260ns | Char | 35 | 60n Specify other opiate w/acetaminophen |
| 209 | bg261 | Char | 1 | 61 Histamine H2 receptor antagonists |
| 210 | bg261a | Char | 1 | 61a Cimetidine |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 211 | bg261b | Char | 1 | 61b Esomeprazole magnesium |
| 212 | bg261c | Char | 1 | 61c Famotidine |
| 213 | bg261d | Char | 1 | 61d Lansoprazole |
| 214 | bg261e | Char | 1 | 61e Nizatidine |
| 215 | bg261f | Char | 1 | 61f Omeprazole |
| 216 | bg261g | Char | 1 | 61g Ranitidine |
| 217 | bg261h | Char | 1 | 61h Ranitidine bismuth citrate |
| 218 | bg261i | Char | 1 | 61i Antacids |
| 219 | bg261is | Char | 35 | 61i Specify antacids |
| 220 | bg261j | Char | 1 | 61j Other |
| 221 | bg261js | Char | 35 | 61j Specify other |
| 222 | bg262 | Char | 1 | 62 Anticoagulant/antiplatelet medications |
| 223 | bg262a | Char | 1 | 62a Clopidogrel |
| 224 | bg262b | Char | 1 | 62b Dipyridamole |
| 225 | bg262c | Char | 1 | 62c Heparin |
| 226 | bg262d | Char | 1 | 62d Ticlopidine |
| 227 | bg262e | Char | 1 | 62e Warfarin |
| 228 | bg262f | Char | 1 | 62f Other anticoagulant |
| 229 | bg262fs | Char | 35 | 62f Specify other anticoagulant |
| 230 | bg263 | Char | 1 | 63 Systemic corticosteroids |
| 231 | bg263a | Char | 1 | 63a Betamethasone sodium |
| 232 | bg263b | Char | 1 | 63b Cortisol |
| 233 | bg263c | Char | 1 | 63c Cortisone |
| 234 | bg263d | Char | 1 | 63d Dexamethasone |
| 235 | bg263e | Char | 1 | 63e Hydrocortisone |
| 236 | bg263f | Char | 1 | 63f Methylprednisolone |
| 237 | bg263g | Char | 1 | 63g Prednisolone |
| 238 | bg263h | Char | 1 | 63h Prednisone |
| 239 | bg263i | Char | 1 | 63i Triamcinolone |
| 240 | bg263j | Char | 1 | 63j Other systemic corticosteroids |
| 241 | bg263js | Char | 35 | 63j Specify other systemic corticosteroids |
| 242 | bg264 | Char | 1 | 64 Cardiovascular/antihypertensive medications |
| 243 | bg264a | Char | 1 | 64a Amiodarone |
| 244 | bg264b | Char | 1 | 64b Amlodipine besylate |
| 245 | bg264c | Char | 1 | 64c Atenolol |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 246 | bg264d | Char | 1 | 64d Benazepril |
| 247 | bg264e | Char | 1 | 64e Captopril |
| 248 | bg264f | Char | 1 | 64f Clonidine |
| 249 | bg264g | Char | 1 | 64g Digoxin |
| 250 | bg264h | Char | 1 | 64h Diltiazem |
| 251 | bg264i | Char | 1 | 64i Doxazosin |
| 252 | bg264j | Char | 1 | 64j Enalapril |
| 253 | bg264k | Char | 1 | 64k Felodipine |
| 254 | bg264l | Char | 1 | 64l Furosemide |
| 255 | bg264m | Char | 1 | 64m Hydrochlorothiazide |
| 256 | bg264n | Char | 1 | 64n Hydrochlorothiazide + triamterene |
| 257 | bg264o | Char | 1 | 64o Lisinopril |
| 258 | bg264p | Char | 1 | 64p Losartan potassium |
| 259 | bg264q | Char | 1 | 64q Losartan potassium with hydrochlorothiazide |
| 260 | bg264r | Char | 1 | 64r Metoprolol |
| 261 | bg264s | Char | 1 | 64s Nifedipine |
| 262 | bg264t | Char | 1 | 64t Perhexiline maleate |
| 263 | bg264u | Char | 1 | 64u Propranolol |
| 264 | bg264v | Char | 1 | 64v Quinapril |
| 265 | bg264w | Char | 1 | 64w Terazosin |
| 266 | bg264x | Char | 1 | 64x Timolol maleate |
| 267 | bg264y | Char | 1 | 64y Valsartan |
| 268 | bg264z | Char | 1 | 64z Verapamil |
| 269 | bg264aa | Char | 1 | 64aa Other cardiovascular/antihypertensive |
| 270 | bg264aas | Char | 35 | 64aa Specify other cardiovascular/antihypertensive |
| 271 | bg264ab | Char | 1 | 64ab Other cardiovascular/antihypertensive |
| 272 | bg264abs | Char | 35 | 64ab Specify other cardiovascular/antihypertensive |
| 273 | bg265 | Char | 1 | 65 Estrogen, progestin, HRT medications |
| 274 | bg265a | Char | 1 | 65a Conjugated estrogen |
| 275 | bg265b | Char | 1 | 65b Diethylstilbestrol and methyltestosterone |
| 276 | bg265c | Char | 1 | 65c Esterified estrogen |
| 277 | bg265d | Char | 1 | 65d Estradiol |
| 278 | bg265e | Char | 1 | 65e Ethinyl estradiol |
| 279 | bg265f | Char | 1 | 65f Fluoxymesterone |
| 280 | bg265g | Char | 1 | 65g Levonorgestrel |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 281 | bg265h | Char | 1 | 65h Medroxyprogesterone |
| 282 | bg265i | Char | 1 | 65i Megestrol |
| 283 | bg265j | Char | 1 | 65j Methyltestosterone |
| 284 | bg265k | Char | 1 | 65k Nandrolone |
| 285 | bg265l | Char | 1 | 65l Norethindrone |
| 286 | bg265m | Char | 1 | 65m Norgestrel |
| 287 | bg265n | Char | 1 | 65n Oral contraceptives |
| 288 | bg265o | Char | 1 | 65o Oxandrolone |
| 289 | bg265p | Char | 1 | 65p Oxymetholone |
| 290 | bg265q | Char | 1 | 65q Progesterone |
| 291 | bg265r | Char | 1 | 65r Raloxifene |
| 292 | bg265s | Char | 1 | 65s Tamoxifen |
| 293 | bg265t | Char | 1 | 65t Other hormone replacements |
| 294 | bg265ts | Char | 35 | 65t Specify other hormone replacements |
| 295 | bg265u | Char | 1 | 65u Other hormone replacements |
| 296 | bg265us | Char | 35 | 65u Specify other hormone replacements |
| 297 | bg266 | Char | 1 | 66 Allergy or asthma medications |
| 298 | bg266a | Char | 1 | 66a Beclomethasone dipropionate |
| 299 | bg266b | Char | 1 | 66b Budesonide |
| 300 | bg266c | Char | 1 | 66c Fluticasone propionate |
| 301 | bg266d | Char | 1 | 66d Loratadine |
| 302 | bg266e | Char | 1 | 66e Mometasone furoate |
| 303 | bg266f | Char | 1 | 66f Triamcinolone acetoneide |
| 304 | bg266g | Char | 1 | 66g Other asthma medications |
| 305 | bg266gs | Char | 35 | 66g Specify other asthma medications |
| 306 | bg266h | Char | 1 | 66h Other asthma medications |
| 307 | bg266hs | Char | 35 | 66h Specify other asthma medications |
| 308 | bg267 | Char | 1 | 67 Taken a multivitamin in past 6 months |
| 309 | bg268 | Char | 1 | 68 Taken other vitamins in past 6 months |
| 310 | bg269a | Char | 1 | 69a Vitamin B |
| 311 | bg269b | Char | 1 | 69b Vitamin C |
| 312 | bg269c | Char | 1 | 69c Vitamin D |
| 313 | bg269d | Char | 1 | 69d Vitamin E |
| 314 | bg269e | Char | 1 | 69e Other vitamins |
| 315 | bg269es | Char | 35 | 69e Specify other vitamins |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 316 | bg270 | Char | 1 | 70 Supplements in past 3 months |
| 317 | bg270a | Char | 1 | 70a Alpha-lipoic acid |
| 318 | bg270b | Char | 1 | 70b Alpha-tocopherol |
| 319 | bg270c | Char | 1 | 70c Beta-carotene |
| 320 | bg270d | Char | 1 | 70d Betaine |
| 321 | bg270e | Char | 1 | 70e Calcium |
| 322 | bg270f | Char | 1 | 70f Carnitine |
| 323 | bg270g | Char | 1 | 70g Chondroitin |
| 324 | bg270h | Char | 1 | 70h Choline + methionine...+ pyridoxine |
| 325 | bg270i | Char | 1 | 70i Cod liver oil |
| 326 | bg270j | Char | 1 | 70j Coenzyme Q |
| 327 | bg270k | Char | 1 | 70k Dichloroacetate |
| 328 | bg270l | Char | 1 | 70l Echinacea |
| 329 | bg270m | Char | 1 | 70m Fish oil |
| 330 | bg270n | Char | 1 | 70n Flax seed oil |
| 331 | bg270o | Char | 1 | 70o Garlic |
| 332 | bg270p | Char | 1 | 70p Ginkgo biloba |
| 333 | bg270q | Char | 1 | 70q Glucosamine |
| 334 | bg270r | Char | 1 | 70r Lecithin |
| 335 | bg270s | Char | 1 | 70s Magnesium |
| 336 | bg270t | Char | 1 | 70t Milk thistle |
| 337 | bg270u | Char | 1 | 70u N-acetyl-cysteine |
| 338 | bg270v | Char | 1 | 70v Potassium |
| 339 | bg270w | Char | 1 | 70w S-adenylmethionine |
| 340 | bg270x | Char | 1 | 70x Saw palmetto |
| 341 | bg270y | Char | 1 | 70y Selenium |
| 342 | bg270z | Char | 1 | 70z St John's Wort |
| 343 | bg270aa | Char | 1 | 70aa Taurine |
| 344 | bg270ab | Char | 1 | 70ab Zinc picolinate |
| 345 | bg270ac | Char | 1 | 70ac Other supplements |
| 346 | bg270acs | Char | 35 | 70ac Specify other supplements |
| 347 | bg270ad | Char | 1 | 70ad Other supplements |
| 348 | bg270ads | Char | 35 | 70ad Specify other supplements |
| 349 | bg271 | Char | 1 | 71 Other medications/supplements |
| 350 | bg271a | Char | 1 | 71a Demeclocycline |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 351 | bg271b | Char | 1 | 71b Divalproex |
| 352 | bg271c | Char | 1 | 71c Doxycycline |
| 353 | bg271d | Char | 1 | 71d Isotretinoin |
| 354 | bg271e | Char | 1 | 71e Levothyroxine |
| 355 | bg271f | Char | 1 | 71f Liothyronine |
| 356 | bg271g | Char | 1 | 71g Methotrexate |
| 357 | bg271h | Char | 1 | 71h Minocycline |
| 358 | bg271i | Char | 1 | 71i Oxytetracycline |
| 359 | bg271j | Char | 1 | 71j Penicillamine |
| 360 | bg271k | Char | 1 | 71k Tetracycline |
| 361 | bg271l | Char | 1 | 71l Trientine hydrochloride |
| 362 | bg271m | Char | 1 | 71m Ursodeoxycholic acid |
| 363 | bg271n | Char | 1 | 71n Valproate sodium |
| 364 | bg271o | Char | 1 | 71o Valproic acid |
| 365 | bg271p | Char | 1 | 71p Other |
| 366 | bg271ps | Char | 35 | 71p Specify other |
| 367 | bg271q | Char | 1 | 71q Other |
| 368 | bg271qs | Char | 35 | 71q Specify other |
| 369 | bg271r | Char | 1 | 71r Other |
| 370 | bg271rs | Char | 35 | 71r Specify other |
| 371 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 372 | bg216 | Num | 8 | 16 Diagnosis date: fatty liver dx or cirrhosis (days since enrollment) |
| 373 | bg220 | Num | 8 | 20 Date of liver biopsy (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.BQ | Observations | 3634 |
| Member Type | DATA | Variables | 38 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:01 | Observation Length | 88 |
| Last Modified | 03/10/2023 17:44:01 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 5 |
| First Data Page | 1 |
| Max Obs per Page | 743 |
| Obs in First Data Page | 673 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\bq.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 384KB |
| File Size (bytes) | 393216 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | bq108a | Char | 1 | 08a Water- How often do you drink |
| 6 | bq108b | Char | 1 | 08b Water- How much each time |
| 7 | bq109a | Char | 1 | 09a 100 percent fruit juice- How often do you drink |
| 8 | bq109b | Char | 1 | 09b 100 percent fruit juice- How much each time |
| 9 | bq110a | Char | 1 | 10a Sweetened fruit juice- How often do you drink |
| 10 | bq110b | Char | 1 | 10b Sweetened fruit juice- How much each time |
| 11 | bq111a | Char | 1 | 11a Whole milk- How often do you drink |
| 12 | bq111b | Char | 1 | 11b Whole milk- How much each time |
| 13 | bq112a | Char | 1 | 12a Reduced fat milk- How often do you drink |
| 14 | bq112b | Char | 1 | 12b Reduced fat milk- How much each time |
| 15 | bq113a | Char | 1 | 13a Low fat/Fat free milk- How often do you drink |
| 16 | bq113b | Char | 1 | 13b Low fat/Fat free milk- How much each time |
| 17 | bq114a | Char | 1 | 14a Soft drinks regular- How often do you drink |
| 18 | bq114b | Char | 1 | 14b Soft drinks regular- How much each time |
| 19 | bq115a | Char | 1 | 15a Diet soft drinks- How often do you drink |
| 20 | bq115b | Char | 1 | 15b Diet soft drinks- How much each time |
| 21 | bq116a | Char | 1 | 16a Sweetened tea- How often do you drink |
| 22 | bq116b | Char | 1 | 16b Sweetened tea- How much each time |
| 23 | bq117a | Char | 1 | 17a Tea/coffee with cream/sugar- How often do you drink |
| 24 | bq117b | Char | 1 | 17b Tea/coffee with cream/sugar- How much each time |
| 25 | bq118a | Char | 1 | 18a Tea/coffee black- How often do you drink |
| 26 | bq118b | Char | 1 | 18b Tea/coffee black- How much each time |
| 27 | bq119a | Char | 1 | 19a Beer, ale, wine, coolers- How often do you drink |
| 28 | bq119b | Char | 1 | 19b Beer, ale, wine, coolers- How much each time |
| 29 | bq120a | Char | 1 | 20a Hard liquor- How often do you drink |
| 30 | bq120b | Char | 1 | 20b Hard liquor- How much each time |
| 31 | bq121a | Char | 1 | 21a Wine (red or white)- How often do you drink |
| 32 | bq121b | Char | 1 | 21b Wine (red or white)- How much each time |
| 33 | bq122a | Char | 1 | 22a Energy/sports drinks- How often do you drink |
| 34 | bq122b | Char | 1 | 22b Energy/sports drinks- How much each time |
| 35 | bq123a | Char | 1 | 23a Other drinks- How often do you drink |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--------------------------------------|
| # | Variable | Type | Len | Label |
| 36 | bq123b | Char | 1 | 23b Other drinks- How much each time |
| 37 | bq123 | Char | 35 | 23 Specify other drinks |
| 38 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.CG1 | Observations | 1680 |
| Member Type | DATA | Variables | 10 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:02 | Observation Length | 32 |
| Last Modified | 03/10/2023 17:44:02 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 2039 |
| Obs in First Data Page | 1680 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\cg1.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | cg108 | Char | 1 | 8 DNA banked for previous NASH CRN study |
| 6 | cg110 | Char | 1 | 10 Consent to current genetic NAFLD research |
| 7 | cg111 | Char | 1 | 11 Consent to future genetic NAFLD research |
| 8 | cg112 | Char | 1 | 12 Consent to future genetic non NAFLD research |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 9 | cg114 | Char | 1 | 14 Consented to collection of blood for DNA banking |
| 10 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.CG2 | Observations | 684 |
| Member Type | DATA | Variables | 10 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:02 | Observation Length | 32 |
| Last Modified | 03/10/2023 17:44:02 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 2039 |
| Obs in First Data Page | 684 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\cg2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | cg208 | Char | 1 | 8 DNA banked for previous NASH CRN study |
| 6 | cg210 | Char | 1 | 10 Consent to current genetic NAFLD research |
| 7 | cg211 | Char | 1 | 11 Consent to future genetic NAFLD research |
| 8 | cg212 | Char | 1 | 12 Consent to future genetic non NAFLD research |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 9 | cg214 | Char | 1 | 14 Consented to collection of blood for DNA banking |
| 10 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.CR2 | Observations | 1137 |
| Member Type | DATA | Variables | 40 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:03 | Observation Length | 72 |
| Last Modified | 03/10/2023 17:44:03 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 2 |
| First Data Page | 1 |
| Max Obs per Page | 908 |
| Obs in First Data Page | 825 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_master\set\Datasets\Adults\cr2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 192KB |
| File Size (bytes) | 196608 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 2 | 7 Study |
| 5 | cr210 | Char | 2 | 10 Biopsy length |
| 6 | cr211 | Char | 1 | 11 Tissue adequate |
| 7 | cr213a | Char | 1 | 13a Steatosis grade |
| 8 | cr213b | Char | 1 | 13b Steatosis location |
| 9 | cr213c | Char | 1 | 13c Type of macrovesicular steatosis |
| 10 | cr213d | Char | 1 | 13d Microvesicular steatosis, contiguous |
| 11 | cr214a | Char | 1 | 14a Amount of lobular inflammation |
| 12 | cr214b | Char | 1 | 14b Microgranulomas seen |
| 13 | cr214c | Char | 1 | 14c Large lipogranulomas seen |
| 14 | cr214d | Char | 1 | 14d Amount of portal, chronic inflammation |
| 15 | cr215a | Char | 1 | 15a Ballooning |
| 16 | cr215b | Char | 1 | 15b Severe ballooning present |
| 17 | cr215c | Char | 1 | 15c Classical balloon cells present |
| 18 | cr215d | Char | 1 | 15d Acidophil bodies |
| 19 | cr215e | Char | 1 | 15e Pigmented macrophages |
| 20 | cr215f | Char | 1 | 15f Megamitochondria |
| 21 | cr216 | Char | 1 | 16 Mallory bodies |
| 22 | cr217 | Char | 1 | 17 Glycogen nuclei |
| 23 | cr218 | Char | 1 | 18 Glycogenosis |
| 24 | cr219a | Char | 2 | 19a Fibrosis stage |
| 25 | cr219b | Char | 1 | 19b Perisinusoidal fibrosis stage |
| 26 | cr219c | Char | 1 | 19c Predominant location of fibrosis |
| 27 | cr220a | Char | 1 | 20a Hepatocellular iron grade |
| 28 | cr220b | Char | 1 | 20b Hepatocellular iron distribution |
| 29 | cr220c | Char | 1 | 20c Nonhepatocellular iron grade |
| 30 | cr220d | Char | 1 | 20d Nonhepatocellular iron distribution |
| 31 | cr221 | Char | 2 | 21 Is this steatohepatitis |
| 32 | cr222 | Char | 1 | 22 Is cirrhosis present |
| 33 | cr223 | Char | 1 | 23 Is this cryptogenic cirrhosis |
| 34 | cr224a | Char | 1 | 24a Mallory-Denk bodies (r/o cholate stasis) |
| 35 | cr224b | Char | 1 | 24b Perisinusoidal fibrosis away from septa |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 36 | cr224c | Char | 1 | 24c Hepatocyte ballooning |
| 37 | cr224d | Char | 1 | 24d Megamitochondria |
| 38 | cr224e | Char | 1 | 24e Other |
| 39 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 40 | cr208 | Num | 8 | 8 Date of biopsy (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.CR3 | Observations | 1029 |
| Member Type | DATA | Variables | 29 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:04 | Observation Length | 56 |
| Last Modified | 03/10/2023 17:44:04 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 1167 |
| Obs in First Data Page | 1029 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_master\set\Datasets\Adults\cr3.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 2 | 7 Study |
| 5 | cr310 | Char | 2 | 10 Biopsy length |
| 6 | cr311 | Char | 1 | 11 Tissue adequate |
| 7 | cr313a | Char | 1 | 13a Steatosis grade |
| 8 | cr313b | Char | 1 | 13b Steatosis location |
| 9 | cr313c | Char | 1 | 13c Type of macrovesicular steatosis |
| 10 | cr313d | Char | 1 | 13d Microvesicular steatosis, contiguous |
| 11 | cr314a | Char | 1 | 14a Amount of lobular inflammation |
| 12 | cr314d | Char | 1 | 14d Amount of portal, chronic inflammation |
| 13 | cr315a | Char | 1 | 15a Ballooning |
| 14 | cr315b | Char | 1 | 15b Severe ballooning present |
| 15 | cr315c | Char | 1 | 15c Classical balloon cells present |
| 16 | cr315d | Char | 1 | 15d Acidophil bodies |
| 17 | cr315f | Char | 1 | 15f Megamitochondria |
| 18 | cr316 | Char | 1 | 16 Mallory-Denk bodies |
| 19 | cr318 | Char | 1 | 18 Glycogenosis |
| 20 | cr319a | Char | 2 | 19a Fibrosis stage |
| 21 | cr319b | Char | 1 | 19b Perisinusoidal fibrosis stage |
| 22 | cr319c | Char | 1 | 19c Predominant location of fibrosis |
| 23 | cr320a | Char | 1 | 20a Hepatocellular iron grade |
| 24 | cr320b | Char | 1 | 20b Hepatocellular iron distribution |
| 25 | cr320c | Char | 1 | 20c Nonhepatocellular iron grade |
| 26 | cr320d | Char | 1 | 20d Nonhepatocellular iron distribution |
| 27 | cr321 | Char | 2 | 21 Is this steatohepatitis |
| 28 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 29 | cr308 | Num | 8 | 8 Date of biopsy (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.CR4 | Observations | 64 |
| Member Type | DATA | Variables | 28 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:04 | Observation Length | 56 |
| Last Modified | 03/10/2023 17:44:04 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 1167 |
| Obs in First Data Page | 64 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_master\set\Datasets\Adults\cr4.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 2 | 7 Study |
| 5 | cr410 | Char | 2 | 10 Biopsy length |
| 6 | cr411 | Char | 1 | 11 Adequate tissue |
| 7 | cr413a | Char | 1 | 13a Steatosis grade |
| 8 | cr413b | Char | 1 | 13b Steatosis location |
| 9 | cr413c | Char | 1 | 13c Type of microvesicular steatosis |
| 10 | cr413d | Char | 1 | 13d Microvesicular steatosis, contiguous |
| 11 | cr414a | Char | 1 | 14a Amount of lobular inflammation |
| 12 | cr414b | Char | 1 | 14b Amount of portal, chronic inflammation |
| 13 | cr414c | Char | 1 | 14c Amount of portal, chronic inflammation expanded |
| 14 | cr414d | Char | 1 | 14d Amount of periportal inflammation |
| 15 | cr414e | Char | 1 | 14e Ductular reaction |
| 16 | cr415a | Char | 1 | 15a Ballooning |
| 17 | cr415b | Char | 1 | 15b Severe ballooning |
| 18 | cr415c | Char | 1 | 15c Classical balloon cells present |
| 19 | cr415d | Char | 1 | 15d Mallory-Denk bodies |
| 20 | cr416a | Char | 2 | 16a Fibrosis stage |
| 21 | cr416b | Char | 1 | 16b Perisinusoidal fibrosis grade |
| 22 | cr416c | Char | 1 | 16c Predominant location of fibrosis |
| 23 | cr417a | Char | 1 | 17a Hepatocellular iron grade |
| 24 | cr417b | Char | 1 | 17b Non-hepatocellular iron grade |
| 25 | cr418 | Char | 2 | 18 Steatohepatitis |
| 26 | cr419 | Char | 1 | 19 Features of regression |
| 27 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 28 | cr408 | Num | 8 | 8 Date of biopsy (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|-----|
| Data Set Name | OTP.DR1 | Observations | 31 |
| Member Type | DATA | Variables | 18 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:05 | Observation Length | 112 |
| Last Modified | 03/10/2023 17:44:05 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 584 |
| Obs in First Data Page | 31 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_master\set\Datasets\Adults\dr1.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | dr109a | Char | 1 | 9a Patient's family |
| 6 | dr109b | Char | 1 | 9b Friend |
| 7 | dr109c | Char | 1 | 9c Health care provider or NASH CRN staff |
| 8 | dr109d | Char | 1 | 9d Newspaper |
| 9 | dr109e | Char | 1 | 9e Funeral parlor/home |
| 10 | dr109f | Char | 1 | 9f Medical record |
| 11 | dr109g | Char | 1 | 9g Medical examiner |
| 12 | dr109h | Char | 1 | 9h Coroner |
| 13 | dr109i | Char | 1 | 9i Other |
| 14 | dr109is | Char | 35 | 9i Specify other |
| 15 | dr111 | Char | 1 | 11 Cause of death |
| 16 | dr111s | Char | 35 | 11 Specify other |
| 17 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 18 | dr108 | Num | 8 | 8, Date of death (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|-----|
| Data Set Name | OTP.DR2 | Observations | 22 |
| Member Type | DATA | Variables | 72 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:06 | Observation Length | 880 |
| Last Modified | 03/10/2023 17:44:06 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 73728 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 83 |
| Obs in First Data Page | 22 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_master\set\Datasets\Adults\dr2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 144KB |
| File Size (bytes) | 147456 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | dr209a | Char | 1 | 9a Patient's family |
| 6 | dr209b | Char | 1 | 9b Friend |
| 7 | dr209c | Char | 1 | 9c Other caregiver |
| 8 | dr209d | Char | 1 | 9d Health care provider or NASH CRN staff |
| 9 | dr209e | Char | 1 | 9e Newspaper |
| 10 | dr209f | Char | 1 | 9f Funeral parlor/home |
| 11 | dr209g | Char | 1 | 9g Medical record |
| 12 | dr209h | Char | 1 | 9h Medical examiner |
| 13 | dr209i | Char | 1 | 9i Coroner |
| 14 | dr209j | Char | 1 | 9j National Death Index (NDI) |
| 15 | dr209k | Char | 1 | 9k Social Security DMF |
| 16 | dr209l | Char | 1 | 9l Other |
| 17 | dr209ls | Char | 50 | 9l Specify other |
| 18 | dr209lt | Char | 50 | 9l Specify other |
| 19 | dr210a | Char | 1 | 10a Place of death |
| 20 | dr210as | Char | 50 | 10a Other place of death |
| 21 | dr211 | Char | 1 | 11 Death certificate obtained |
| 22 | dr212 | Char | 2 | 12 Underlying cause of death |
| 23 | dr212s | Char | 50 | 12 Specify other cause of death |
| 24 | dr213 | Char | 1 | 13 Coronary heart disease |
| 25 | dr214 | Char | 1 | 14 Cardiovascular disease |
| 26 | dr214s | Char | 50 | 14 Specify other CVD death |
| 27 | dr215 | Char | 1 | 15 Liver disease |
| 28 | dr215s | Char | 50 | 15 Specify other liver disease |
| 29 | dr216 | Char | 1 | 16 Malignancy |
| 30 | dr216s | Char | 50 | 16 Specify other malignancy |
| 31 | dr217 | Char | 1 | 17 Gastrointestinal |
| 32 | dr217s | Char | 50 | 17 Specify other GI |
| 33 | dr218 | Char | 1 | 18 Pulmonary |
| 34 | dr218s | Char | 50 | 18 Specify other pulmonary |
| 35 | dr219a | Char | 1 | 19a Coronary hearth disease |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 36 | dr219as | Char | 50 | 19a Specify other CHD |
| 37 | dr219b | Char | 1 | 19b Cerebrovascular disease |
| 38 | dr219c | Char | 1 | 19c Congestive heart failure |
| 39 | dr219d | Char | 1 | 19d Documented arrhythmia |
| 40 | dr219e | Char | 1 | 19e Other cardiovascular disease |
| 41 | dr219es | Char | 50 | 19e Specify other CVD |
| 42 | dr219f | Char | 1 | 19f Diabetes Type 1 |
| 43 | dr219g | Char | 1 | 19g Diabetes Type 2 |
| 44 | dr219h | Char | 1 | 19h Liver disease |
| 45 | dr219hs | Char | 50 | 19h Specify other liver disease |
| 46 | dr219i | Char | 1 | 19i Hepatocellular carcinoma (HCC) |
| 47 | dr219j | Char | 1 | 19j Other malignancy (cancer) |
| 48 | dr219js | Char | 50 | 19j Specify other malignancy |
| 49 | dr219k | Char | 1 | 19k Gastrointestinal disease |
| 50 | dr219ks | Char | 50 | 19k Specify other GI disease |
| 51 | dr219l | Char | 1 | 19l Pulmonary disease |
| 52 | dr219ls | Char | 50 | 19l Specify other pulmonary disease |
| 53 | dr219m | Char | 1 | 19m Pneumonia |
| 54 | dr219n | Char | 1 | 19n Kidney disease |
| 55 | dr219o | Char | 1 | 19o Sepsis, staph, other infection |
| 56 | dr219p | Char | 1 | 19p Other contributing cause of death |
| 57 | dr219ps | Char | 50 | 19p Specify other contributing cause of death |
| 58 | dr219q | Char | 1 | 19q Unknown |
| 59 | dr219r | Char | 1 | 19r No contributing cause of death |
| 60 | dr220 | Char | 1 | 20 Procedure-related death |
| 61 | dr221 | Char | 1 | 21 Type of procedure-related death |
| 62 | dr222 | Char | 1 | 22 Autopsy performed |
| 63 | dr223a | Char | 1 | 23a Medical records documentation |
| 64 | dr223b | Char | 1 | 23b Autopsy report findings |
| 65 | dr223c | Char | 1 | 23c Death certificate |
| 66 | dr223d | Char | 1 | 23d ER record |
| 67 | dr223e | Char | 1 | 23e EMS report |
| 68 | dr223f | Char | 1 | 23f Informant interview |
| 69 | dr223g | Char | 1 | 23g Coronor's report |
| 70 | dr223h | Char | 1 | 23h Other |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 71 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 72 | dr208 | Num | 8 | 8, Date of death (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|-----|
| Data Set Name | OTP.FR1 | Observations | 184 |
| Member Type | DATA | Variables | 29 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:06 | Observation Length | 152 |
| Last Modified | 03/10/2023 17:44:06 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 430 |
| Obs in First Data Page | 184 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\fr1.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | fr108 | Char | 1 | 8 Patient signed FibrScan consent |
| 6 | fr109a | Char | 1 | 9a Active implant |
| 7 | fr109b | Char | 1 | 9b Wound near site of scan |
| 8 | fr109c | Char | 1 | 9c Pregnancy |
| 9 | fr109d | Char | 1 | 9d Ascites |
| 10 | fr109e | Char | 1 | 9e Patient did not fast for 3 hours |
| 11 | fr109f | Char | 1 | 9f Any of above items checked |
| 12 | fr110 | Char | 1 | 10 Was FibroScan exam performed |
| 13 | fr111a | Char | 1 | 11a Skin-to-capsule distance>3.5cm |
| 14 | fr111b | Char | 1 | 11b Other reason exam not performed |
| 15 | fr111bs | Char | 35 | 11b Specify other reason exam not performed |
| 16 | fr112 | Char | 1 | 12 Probe type used |
| 17 | fr114 | Char | 2 | 14 Number of valid measurements |
| 18 | fr115a | Num | 8 | 15a Median (kPa) Equivalent liver stiffness |
| 19 | fr115b | Num | 8 | 15b IQR (kPa) Equivalent liver stiffness |
| 20 | fr115c | Num | 8 | 15c IQR/Med (%) Equivalent liver stiffness |
| 21 | fr116a | Num | 8 | 16a Median CAP (dB/m) |
| 22 | fr116b | Num | 8 | 16b IQR CAP (dB/m) |
| 23 | fr118 | Char | 2 | 18 Number of valid measurements |
| 24 | fr119a | Num | 8 | 19a Median (kPa) Equivalent liver stiffness |
| 25 | fr119 | Num | 8 | 19b IQR (kPa) Equivalent liver stiffness |
| 26 | fr119c | Num | 8 | 19c IQR/Med (%) Equivalent liver stiffness |
| 27 | fr120a | Num | 8 | 20a Median CAP (dB/m) |
| 28 | fr120b | Num | 8 | 20b IQR CAP (dB/m) |
| 29 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|-----|
| Data Set Name | OTP.FR2 | Observations | 209 |
| Member Type | DATA | Variables | 29 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:07 | Observation Length | 152 |
| Last Modified | 03/10/2023 17:44:07 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 430 |
| Obs in First Data Page | 209 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\fr2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | fr208 | Char | 1 | 8 Patient signed FibrScan consent |
| 6 | fr209a | Char | 1 | 9a Active implant |
| 7 | fr209b | Char | 1 | 9b Wound near site of scan |
| 8 | fr209c | Char | 1 | 9c Pregnancy |
| 9 | fr209d | Char | 1 | 9d Ascites |
| 10 | fr209e | Char | 1 | 9e Patient did not fast for 3 hours |
| 11 | fr209f | Char | 1 | 9f Any of above items checked |
| 12 | fr210 | Char | 1 | 10 Was FibroScan exam performed |
| 13 | fr211a | Char | 1 | 11a Skin-to-capsule distance>3.5cm |
| 14 | fr211b | Char | 1 | 11b Other reason exam not performed |
| 15 | fr211bs | Char | 35 | 11b Specify other reason exam not performed |
| 16 | fr212 | Char | 1 | 12 Probe type used |
| 17 | fr214 | Char | 2 | 14 Number of valid measurements |
| 18 | fr215a | Num | 8 | 15a Median (kPa) Equivalent liver stiffness |
| 19 | fr215b | Num | 8 | 15b IQR (kPa) Equivalent liver stiffness |
| 20 | fr215c | Num | 8 | 15c IQR/Med (%) Equivalent liver stiffness |
| 21 | fr216a | Num | 8 | 16a Median CAP (dB/m) |
| 22 | fr216b | Num | 8 | 16b IQR CAP (dB/m) |
| 23 | fr218 | Char | 2 | 18 Number of valid measurements |
| 24 | fr219a | Num | 8 | 19a Median (kPa) Equivalent liver stiffness |
| 25 | fr219 | Num | 8 | 19b IQR (kPa) Equivalent liver stiffness |
| 26 | fr219c | Num | 8 | 19c IQR/Med (%) Equivalent liver stiffness |
| 27 | fr220a | Num | 8 | 20a Median CAP (dB/m) |
| 28 | fr220b | Num | 8 | 20b IQR CAP (dB/m) |
| 29 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.FR3 | Observations | 65 |
| Member Type | DATA | Variables | 27 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:07 | Observation Length | 136 |
| Last Modified | 03/10/2023 17:44:07 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 481 |
| Obs in First Data Page | 65 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\fr3.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | fr308 | Char | 1 | 8 Patient signed FibroScan consent |
| 6 | fr309a | Char | 1 | 9a Active implant |
| 7 | fr309b | Char | 1 | 9b Wound near site of scan |
| 8 | fr309c | Char | 1 | 9c Pregnancy |
| 9 | fr309d | Char | 1 | 9d Ascites |
| 10 | fr309e | Char | 1 | 9e Patient did not fast for 3 hours |
| 11 | fr309f | Char | 1 | 9f Any of above items checked |
| 12 | fr310 | Char | 1 | 10 Was FibroScan exam performed |
| 13 | fr311a | Char | 1 | 11a Skin-to-capsule distance>3.5cm |
| 14 | fr311b | Char | 1 | 11b Other reason exam not performed |
| 15 | fr311bs | Char | 35 | 11b Specify other reason exam not performed |
| 16 | fr312 | Char | 1 | 12 Probe type used |
| 17 | fr314 | Char | 2 | 14 Number of valid measurements |
| 18 | fr315a | Num | 8 | 15a Median (kPa) Equivalent liver stiffness |
| 19 | fr315b | Num | 8 | 15b IQR (kPa) Equivalent liver stiffness |
| 20 | fr315c | Num | 8 | 15c IQR/Med (%) Equivalent liver stiffness |
| 21 | fr316a | Num | 8 | 16a Median CAP (dB/m) |
| 22 | fr318 | Char | 2 | 18 Number of valid measurements |
| 23 | fr319a | Num | 8 | 19a Median (kPa) Equivalent liver stiffness |
| 24 | fr319 | Num | 8 | 19b IQR (kPa) Equivalent liver stiffness |
| 25 | fr319c | Num | 8 | 19c IQR/Med (%) Equivalent liver stiffness |
| 26 | fr320a | Num | 8 | 20a Median CAP (dB/m) |
| 27 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|------|
| Data Set Name | OTP.FR4 | Observations | 1187 |
| Member Type | DATA | Variables | 29 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:08 | Observation Length | 144 |
| Last Modified | 03/10/2023 17:44:08 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 3 |
| First Data Page | 1 |
| Max Obs per Page | 454 |
| Obs in First Data Page | 422 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\fr4.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 256KB |
| File Size (bytes) | 262144 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | fr408 | Char | 1 | 8 Patient signed FibroScan consent |
| 6 | fr409a | Char | 1 | 9a Active implant |
| 7 | fr409b | Char | 1 | 9b Wound near site of scan |
| 8 | fr409c | Char | 1 | 9c Pregnancy |
| 9 | fr409d | Char | 1 | 9d Ascites |
| 10 | fr409e | Char | 1 | 9e Patient did not fast for 3 hours |
| 11 | fr409f | Char | 1 | 9f Any of above items checked |
| 12 | fr410 | Char | 1 | 10 Was FibroScan exam performed |
| 13 | fr411a | Char | 1 | 11a Skin-to-capsule distance>3.5cm |
| 14 | fr411b | Char | 1 | 11b Other reason exam not performed |
| 15 | fr411bs | Char | 35 | 11b Specify other reason exam not performed |
| 16 | fr412 | Char | 1 | 12 Probe type used |
| 17 | fr414a | Char | 2 | 14a Number of valid measurements |
| 18 | fr414b | Char | 2 | 14b Number of invalid measurements |
| 19 | fr415a | Num | 8 | 15a Median (kPa) Equivalent liver stiffness |
| 20 | fr415b | Num | 8 | 15b IQR (kPa) Equivalent liver stiffness |
| 21 | fr415c | Num | 8 | 15c IQR/Med (%) Equivalent liver stiffness |
| 22 | fr416a | Num | 8 | 16a Median CAP (dB/m) |
| 23 | fr418a | Char | 2 | 18a Number of valid measurements |
| 24 | fr418b | Char | 2 | 18b Number of invalid measurements |
| 25 | fr419a | Num | 8 | 19a Median (kPa) Equivalent liver stiffness |
| 26 | fr419 | Num | 8 | 19b IQR (kPa) Equivalent liver stiffness |
| 27 | fr419c | Num | 8 | 19c IQR/Med (%) Equivalent liver stiffness |
| 28 | fr420a | Num | 8 | 20a Median CAP (dB/m) |
| 29 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.FR5 | Observations | 3352 |
| Member Type | DATA | Variables | 33 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:09 | Observation Length | 160 |
| Last Modified | 03/10/2023 17:44:09 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 9 |
| First Data Page | 1 |
| Max Obs per Page | 409 |
| Obs in First Data Page | 377 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\fr5.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 640KB |
| File Size (bytes) | 655360 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | fr508 | Char | 1 | 8 Patient signed FibroScan consent |
| 6 | fr509a | Char | 1 | 9a Active implant |
| 7 | fr509b | Char | 1 | 9b Wound near site of scan |
| 8 | fr509c | Char | 1 | 9c Pregnancy |
| 9 | fr509d | Char | 1 | 9d Ascites |
| 10 | fr509e | Char | 1 | 9e Patient did not fast for 3 hours |
| 11 | fr509f | Char | 1 | 9f Any of above items checked |
| 12 | fr510 | Char | 1 | 10 Was FibroScan exam performed |
| 13 | fr511a | Char | 1 | 11a Skin-to-capsule distance>3.5cm |
| 14 | fr511b | Char | 1 | 11b Other reason exam not performed |
| 15 | fr511bs | Char | 35 | 11b Specify other reason exam not performed |
| 16 | fr512 | Char | 1 | 12 Probe type used |
| 17 | fr514a | Char | 2 | 14a Number of valid measurements |
| 18 | fr514b | Char | 2 | 14b Number of invalid measurements |
| 19 | fr514c | Char | 2 | 14c Total number of measurements |
| 20 | fr515a | Num | 8 | 15a Median (kPa) Equivalent liver stiffness |
| 21 | fr515b | Num | 8 | 15b IQR (kPa) Equivalent liver stiffness |
| 22 | fr515c | Num | 8 | 15c IQR/Med (%) Equivalent liver stiffness |
| 23 | fr516a | Num | 8 | 16a Median CAP (dB/m) |
| 24 | fr516b | Num | 8 | 16b IQR CAP (dB/m) |
| 25 | fr518a | Char | 2 | 18a Number of valid measurements |
| 26 | fr518b | Char | 2 | 18b Number of invalid measurements |
| 27 | fr518c | Char | 2 | 18c Number of total of measurements |
| 28 | fr519a | Num | 8 | 19a Median (kPa) Equivalent liver stiffness |
| 29 | fr519 | Num | 8 | 19b IQR (kPa) Equivalent liver stiffness |
| 30 | fr519c | Num | 8 | 19c IQR/Med (%) Equivalent liver stiffness |
| 31 | fr520a | Num | 8 | 20a Median CAP (dB/m) |
| 32 | fr520b | Num | 8 | 20b IQR CAP (dB/m) |
| 33 | formdate | Num | 8 | 4 Form date (days since enrollment) |

The CONTENTS Procedure

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.HC | Observations | 7 |
| Member Type | DATA | Variables | 17 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 18:26:58 | Observation Length | 96 |
| Last Modified | 03/10/2023 18:26:58 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 681 |
| Obs in First Data Page | 7 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\hc.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | hc109a | Char | 1 | 9a Ultrasound |
| 6 | hc109b | Char | 1 | 9b CT scan |
| 7 | hc109c | Char | 1 | 9c MRI |
| 8 | hc109d | Char | 1 | 9d Biopsy |
| 9 | hc109es | Char | 50 | 9e Specify other |
| 10 | hc110 | Char | 1 | 10 Were imaging results obtained |
| 11 | hc111 | Char | 1 | 11 Were multiple tumors identified |
| 12 | hc113 | Char | 1 | 13 Was early enhancement present |
| 13 | hc114 | Char | 1 | 14 Was delayed washout present |
| 14 | hc115a | Char | 1 | 15a Was serum AFP elevated |
| 15 | hc115b | Num | 8 | 15b, Serum AFP level |
| 16 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 17 | hc108 | Num | 8 | 8 Date of diagnosis (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.HI | Observations | 7154 |
| Member Type | DATA | Variables | 203 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:10 | Observation Length | 536 |
| Last Modified | 03/10/2023 17:44:10 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 60 |
| First Data Page | 1 |
| Max Obs per Page | 122 |
| Obs in First Data Page | 75 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositores\limaccds\Dbase2\public_masterset\Datasets\Adults\hi.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 4MB |
| File Size (bytes) | 3997696 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | hi109 | Char | 4 | 9 Visit code of last followup medical history |
| 6 | hi110 | Char | 1 | 10 Liver biopsy since last visit |
| 7 | hi111 | Char | 1 | 11 Abdominal imaging study since last visit |
| 8 | hi112 | Char | 1 | 12 Patient age 12 or older |
| 9 | hi113 | Char | 1 | 13 How often had alcoholic drink |
| 10 | hi114 | Char | 1 | 14 Number of drinks on a typical day when drinking |
| 11 | hi115 | Char | 1 | 15 How often had 6 or more drinks |
| 12 | hi116 | Char | 1 | 16 Smoked cigarettes regularly since last visit |
| 13 | hi117 | Char | 1 | 17 Number of days smoked per week |
| 14 | hi118 | Char | 3 | 18 Number cigarettes smoked per day |
| 15 | hi119a | Char | 1 | 19a Diabetes type 1 |
| 16 | hi119b | Char | 1 | 19b Diabetes type 2 |
| 17 | hi119c | Char | 1 | 19c Gestational diabetes |
| 18 | hi119d | Char | 1 | 19d Hepatitis B |
| 19 | hi119e | Char | 1 | 19e Hepatitis C |
| 20 | hi119f | Char | 1 | 19f Autoimmune hepatitis |
| 21 | hi119g | Char | 1 | 19g Autoimmune cholestatic liver disorder |
| 22 | hi119h | Char | 1 | 19h Wilson's disease |
| 23 | hi119i | Char | 1 | 19i Alpha-1 antitrypsin deficiency |
| 24 | hi119j | Char | 1 | 19j Iron overload |
| 25 | hi119k | Char | 1 | 19k Drug induced liver disease |
| 26 | hi119l | Char | 1 | 19l Gilbert's syndrome |
| 27 | hi119m | Char | 1 | 19m Esophageal or gastric varices on endoscopy |
| 28 | hi119n | Char | 1 | 19n Bleeding from varices |
| 29 | hi119o | Char | 1 | 19o Other gastrointestinal bleeding |
| 30 | hi119p | Char | 1 | 19p Ascites |
| 31 | hi119q | Char | 1 | 19q Edema |
| 32 | hi119r | Char | 1 | 19r Hepatic encephalopathy |
| 33 | hi119s | Char | 1 | 19s Portal hypertension |
| 34 | hi119t | Char | 1 | 19t Hepatorenal syndrome |
| 35 | hi119u | Char | 1 | 19u Hepatopulmonary syndrome |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 36 | hi119v | Char | 1 | 19v Short bowel syndrome |
| 37 | hi119w | Char | 1 | 19w Hemophilia |
| 38 | hi119x | Char | 1 | 19x Systemic autoimmune disorder |
| 39 | hi119y | Char | 1 | 19y Endocrine disease |
| 40 | hi119z | Char | 1 | 19z Hepatocellular carcinoma |
| 41 | hi119aa | Char | 1 | 19aa Other malignancy |
| 42 | hi119ab | Char | 1 | 19ab Peripheral neuropathy |
| 43 | hi119ac | Char | 1 | 19ac Seizure disorder or epilepsy |
| 44 | hi119ad | Char | 1 | 19ad Drug allergies |
| 45 | hi119ae | Char | 1 | 19ae Hypothyroidism |
| 46 | hi119af | Char | 1 | 19af Hypertension |
| 47 | hi119ag | Char | 1 | 19ag Cerebrovascular disease |
| 48 | hi119ah | Char | 1 | 19ah Dysbetalipoproteinemia |
| 49 | hi119ai | Char | 1 | 19ai Hyperlipidemia |
| 50 | hi119aj | Char | 1 | 19aj Pancreatitis |
| 51 | hi119ak | Char | 1 | 19ak Cholelithiasis |
| 52 | hi119al | Char | 1 | 19al Coronary artery disease |
| 53 | hi119am | Char | 1 | 19am Elevated uric acid |
| 54 | hi119an | Char | 1 | 19an Kidney disease |
| 55 | hi119ao | Char | 1 | 19ao Polycystic ovary syndrome |
| 56 | hi119ap | Char | 1 | 19ap Sleep apnea |
| 57 | hi119aq | Char | 1 | 19aq Dermatologic disorders |
| 58 | hi119ar | Char | 1 | 19ar Myopathy |
| 59 | hi119as | Char | 1 | 19as Myositis |
| 60 | hi119at | Char | 1 | 19at Major depression |
| 61 | hi119au | Char | 1 | 19au Schizophrenia |
| 62 | hi119av | Char | 1 | 19av Bipolar disorder |
| 63 | hi119aw | Char | 1 | 19aw Obsessive compulsive disorder |
| 64 | hi119ax | Char | 1 | 19ax Severe anxiety or personality disorder |
| 65 | hi119ay | Char | 1 | 19ay None of the above |
| 66 | hi120a | Char | 1 | 20a Stapling of the stomach |
| 67 | hi120b | Char | 1 | 20b Jejunioileal bypass |
| 68 | hi120c | Char | 1 | 20c Biliopancreatic diversion |
| 69 | hi120d | Char | 1 | 20d Other GI or bariatric surgery |
| 70 | hi120ds | Char | 35 | 20d Specify other |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 71 | hi120e | Char | 1 | 20e None of the above |
| 72 | hi121 | Char | 1 | 21 Received organ/limb/bone marrow transplant |
| 73 | hi122 | Char | 1 | 22 Received TPN since last visit |
| 74 | hi123 | Char | 1 | 23 Undergoing evaluation for bariatric surgery |
| 75 | hi124 | Char | 1 | 24 Been hospitalized since the last visit |
| 76 | hi125 | Char | 1 | 25 Had any serious health problem not already reported |
| 77 | hi126 | Char | 1 | 26 Used any antidiabetic medications |
| 78 | hi126a | Char | 1 | 26a Acarbose |
| 79 | hi126b | Char | 1 | 26b Acetohexamide |
| 80 | hi126c | Char | 1 | 26c Chlorpropamide |
| 81 | hi126d | Char | 1 | 26d Glimepiride |
| 82 | hi126e | Char | 1 | 26e Glipizide |
| 83 | hi126f | Char | 1 | 26f Glyburide |
| 84 | hi126g | Char | 1 | 26g Insulin |
| 85 | hi126h | Char | 1 | 26h Metformin |
| 86 | hi126i | Char | 1 | 26i Miglitol |
| 87 | hi126j | Char | 1 | 26j Nateglinide |
| 88 | hi126k | Char | 1 | 26k Pioglitazone |
| 89 | hi126l | Char | 1 | 26l Repaglinide |
| 90 | hi126m | Char | 1 | 26m Rosiglitazone |
| 91 | hi126n | Char | 1 | 26n Tolazamide |
| 92 | hi126o | Char | 1 | 26o Tolbutamide |
| 93 | hi126p | Char | 1 | 26p Other |
| 94 | hi126ps | Char | 35 | 26p Specify other |
| 95 | hi127 | Char | 1 | 27 Alcohol abuse medication |
| 96 | hi128 | Char | 1 | 28 Antihyperlipidemic medications |
| 97 | hi128a | Char | 1 | 28a Atorvastatin |
| 98 | hi128b | Char | 1 | 28b Colestipol hydrochloride |
| 99 | hi128c | Char | 1 | 28c Clofibrate |
| 100 | hi128d | Char | 1 | 28d Gemfibrozil |
| 101 | hi128e | Char | 1 | 28e Fenofibrate |
| 102 | hi128f | Char | 1 | 28f Fluvastatine sodium |
| 103 | hi128g | Char | 1 | 28g Lovastatin |
| 104 | hi128h | Char | 1 | 28h Nicotinic acid |
| 105 | hi128i | Char | 1 | 28i Pravastatin sodium |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 106 | hi128j | Char | 1 | 28j Rosuvastatin |
| 107 | hi128k | Char | 1 | 28k Simvastatin |
| 108 | hi128l | Char | 1 | 28l Other |
| 109 | hi128ls | Char | 35 | 28l Specify other |
| 110 | hi129 | Char | 1 | 29 Antiobesity medication since last visit |
| 111 | hi130 | Char | 1 | 30 Systemic corticosteroids since last visit |
| 112 | hi131 | Char | 1 | 31 Cardiovascular/antihypertensives |
| 113 | hi131a | Char | 1 | 31a Amiodarone |
| 114 | hi131b | Char | 1 | 31b Amlodipine besylate |
| 115 | hi131c | Char | 1 | 31c Atenolol |
| 116 | hi131d | Char | 1 | 31d Benazepril |
| 117 | hi131e | Char | 1 | 31e Captopril |
| 118 | hi131f | Char | 1 | 31f Clonidine |
| 119 | hi131g | Char | 1 | 31g Digoxin |
| 120 | hi131h | Char | 1 | 31h Diltiazem |
| 121 | hi131i | Char | 1 | 31i Doxazosin |
| 122 | hi131j | Char | 1 | 31j Enalapril |
| 123 | hi131k | Char | 1 | 31k Felodipine |
| 124 | hi131l | Char | 1 | 31l Furosemide |
| 125 | hi131m | Char | 1 | 31m Hydrochlorothiazide |
| 126 | hi131n | Char | 1 | 31n Hydrochlorothiazide + triamterene |
| 127 | hi131o | Char | 1 | 31o Lisinopril |
| 128 | hi131p | Char | 1 | 31p Losartan potassium |
| 129 | hi131q | Char | 1 | 31q Losartan potassium with hydrochlorothiazide |
| 130 | hi131r | Char | 1 | 31r Metoprolol |
| 131 | hi131s | Char | 1 | 31s Nifedipine |
| 132 | hi131t | Char | 1 | 31t Perhexiline maleate |
| 133 | hi131u | Char | 1 | 31u Propranolol |
| 134 | hi131v | Char | 1 | 31v Quinapril |
| 135 | hi131w | Char | 1 | 31w Terazosin |
| 136 | hi131x | Char | 1 | 31x Timolol maleate |
| 137 | hi131y | Char | 1 | 31y Valsartan |
| 138 | hi131z | Char | 1 | 31z Verapamil |
| 139 | hi131aa | Char | 1 | 31aa Other |
| 140 | hi131aas | Char | 31 | 31aa Specify other |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 141 | hi131ab | Char | 1 | 31ab Other |
| 142 | hi131abs | Char | 31 | 31ab Specify other |
| 143 | hi132 | Char | 1 | 32 Hormones since last visit |
| 144 | hi132a | Char | 1 | 32a Oral contraceptives |
| 145 | hi132b | Char | 1 | 32b Raloxifene |
| 146 | hi132c | Char | 1 | 32c Tamoxifen |
| 147 | hi132d | Char | 1 | 32d Other |
| 148 | hi132ds | Char | 35 | 32d Specify other |
| 149 | hi133 | Char | 1 | 33 Vitamins or supplements |
| 150 | hi133a | Char | 1 | 33a Multivitamin |
| 151 | hi133b | Char | 1 | 33b Vitamin B |
| 152 | hi133c | Char | 1 | 33c Vitamin C |
| 153 | hi133d | Char | 1 | 33d Vitamin D |
| 154 | hi133e | Char | 1 | 33e Vitamin E |
| 155 | hi133f | Char | 1 | 33f Alpha-lipoic acid |
| 156 | hi133g | Char | 1 | 33g Alpha-tocopherol |
| 157 | hi133h | Char | 1 | 33h Beta-carotene |
| 158 | hi133i | Char | 1 | 33i Betaine |
| 159 | hi133j | Char | 1 | 33j Calcium |
| 160 | hi133k | Char | 1 | 33k Carnitine |
| 161 | hi133l | Char | 1 | 33l Choline + methionine...+ pyridoxine |
| 162 | hi133m | Char | 1 | 33m Cod liver oil |
| 163 | hi133n | Char | 1 | 33n Coenzyme Q |
| 164 | hi133o | Char | 1 | 33o Echinacea |
| 165 | hi133p | Char | 1 | 33p Fish oil |
| 166 | hi133q | Char | 1 | 33q Flax seed oil |
| 167 | hi133r | Char | 1 | 33r Garlic |
| 168 | hi133s | Char | 1 | 33s Ginko biloba |
| 169 | hi133t | Char | 1 | 33t Glucosamine |
| 170 | hi133u | Char | 1 | 33u Lecithin |
| 171 | hi133v | Char | 1 | 33v Milk thistle |
| 172 | hi133w | Char | 1 | 33w N-acetyl-cysteine |
| 173 | hi133x | Char | 1 | 33x S-adenylmethionine |
| 174 | hi133y | Char | 1 | 33y Saw palmetto |
| 175 | hi133z | Char | 1 | 33z Selenium |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 176 | hi133aa | Char | 1 | 33aa St John's Wort |
| 177 | hi133ab | Char | 1 | 33ab Taurine |
| 178 | hi133ac | Char | 1 | 33ac Zinc picolinate |
| 179 | hi133ad | Char | 1 | 33ad Other |
| 180 | hi133ads | Char | 35 | 33ad Specify other |
| 181 | hi134 | Char | 1 | 34 Other supplements/medications |
| 182 | hi134a | Char | 1 | 34a Demeclocycline |
| 183 | hi134b | Char | 1 | 34b Divalproex |
| 184 | hi134c | Char | 1 | 34c Doxycycline |
| 185 | hi134d | Char | 1 | 34d Isotretinoin |
| 186 | hi134e | Char | 1 | 34e Levothyroxine |
| 187 | hi134f | Char | 1 | 34f Liothyronine |
| 188 | hi134g | Char | 1 | 34g Methotrexate |
| 189 | hi134h | Char | 1 | 34h Minocycline |
| 190 | hi134i | Char | 1 | 34i Oxytetracycline |
| 191 | hi134j | Char | 1 | 34j Tetracycline |
| 192 | hi134k | Char | 1 | 34k Ursodeoxycholic acid |
| 193 | hi134l | Char | 1 | 34l Valproate sodium |
| 194 | hi134m | Char | 1 | 34m Valproic acid |
| 195 | hi134n | Char | 1 | 34n Other |
| 196 | hi134ns | Char | 35 | 34n Specify other |
| 197 | hi134o | Char | 1 | 34o Other |
| 198 | hi134os | Char | 35 | 34o Specify other |
| 199 | hi135 | Char | 1 | 35 Aspirin, anti-inflammatory |
| 200 | hi136a | Char | 1 | 36a Rate the patient's ascites |
| 201 | hi136b | Char | 1 | 36b Rate the patient's hepatic encephalopathy |
| 202 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 203 | hi108 | Num | 8 | 8 Date of last HI form (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.IE1 | Observations | 28 |
| Member Type | DATA | Variables | 23 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:10 | Observation Length | 128 |
| Last Modified | 03/10/2023 17:44:10 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 511 |
| Obs in First Data Page | 28 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\ie1.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ie113a | Char | 1 | 13a General anesthesia |
| 6 | ie113b | Char | 1 | 13b Study procedure related event |
| 7 | ie113c | Char | 1 | 13c Drug interaction |
| 8 | ie113d | Char | 1 | 13d Worsening of co-morbid illness |
| 9 | ie113e | Char | 1 | 13e Hypoglycemia |
| 10 | ie113f | Char | 1 | 13f New-onset diabetes |
| 11 | ie113g | Char | 1 | 13g Pregnancy |
| 12 | ie113h | Char | 1 | 13h Other type of event |
| 13 | ie114a | Char | 1 | 14a Emergency room visit |
| 14 | ie114b | Char | 1 | 14b Hospitalization |
| 15 | ie114c | Char | 1 | 14c Infectious episode |
| 16 | ie114d | Char | 1 | 14d Surgical intervention |
| 17 | ie116 | Char | 1 | 16 No short name for AE |
| 18 | ie116s | Char | 35 | 16 Short name for AE |
| 19 | ie116t | Char | 35 | 16 Short name for AE |
| 20 | ie117 | Char | 1 | 17 Severity grade |
| 21 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 22 | ie112 | Num | 8 | 12, Date event started (days since enrollment) |
| 23 | ie118 | Num | 8 | 18, Date event resolved (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.IE2 | Observations | 5 |
| Member Type | DATA | Variables | 23 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:11 | Observation Length | 104 |
| Last Modified | 03/10/2023 17:44:11 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 629 |
| Obs in First Data Page | 5 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\ie2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ie213a | Char | 1 | 13a General anesthesia |
| 6 | ie213b | Char | 1 | 13b Study procedure related event |
| 7 | ie213c | Char | 1 | 13c Drug interaction |
| 8 | ie213d | Char | 1 | 13d Worsening of co-morbid illness |
| 9 | ie213e | Char | 1 | 13e Hypoglycemia |
| 10 | ie213f | Char | 1 | 13f New-onset diabetes |
| 11 | ie213g | Char | 1 | 13g Pregnancy |
| 12 | ie213h | Char | 1 | 13h Cirrhosis |
| 13 | ie213i | Char | 1 | 13i Hepatocellular carcinoma |
| 14 | ie213j | Char | 1 | 13j Other type of event |
| 15 | ie214a | Char | 1 | 14a Emergency room visit |
| 16 | ie214b | Char | 1 | 14b Hospitalization |
| 17 | ie214c | Char | 1 | 14c Infectious episode |
| 18 | ie214d | Char | 1 | 14d Surgical intervention |
| 19 | ie216s | Char | 50 | 16 Short name for AE |
| 20 | ie217 | Char | 1 | 17 Severity grade |
| 21 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 22 | ie212 | Num | 8 | 12, Date event started (days since enrollment) |
| 23 | ie218 | Num | 8 | 18, Date event resolved (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|-----|
| Data Set Name | OTP.IE3 | Observations | 335 |
| Member Type | DATA | Variables | 25 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:11 | Observation Length | 160 |
| Last Modified | 03/10/2023 17:44:11 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 1 |
| First Data Page | 1 |
| Max Obs per Page | 409 |
| Obs in First Data Page | 335 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\ie3.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 128KB |
| File Size (bytes) | 131072 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ie313a | Char | 1 | 13a General anesthesia |
| 6 | ie313b | Char | 1 | 13b Study procedure related event |
| 7 | ie313c | Char | 1 | 13c Drug interaction |
| 8 | ie313d | Char | 1 | 13d Worsening of co-morbid illness |
| 9 | ie313e | Char | 1 | 13e Hypoglycemia |
| 10 | ie313f | Char | 1 | 13f New-onset diabetes |
| 11 | ie313g | Char | 1 | 13g Pregnancy |
| 12 | ie313h | Char | 1 | 13h Cirrhosis |
| 13 | ie313i | Char | 1 | 13i Hepatocellular carcinoma |
| 14 | ie313j | Char | 1 | 13j Other type of event |
| 15 | ie314a | Char | 1 | 14a Emergency room visit |
| 16 | ie314b | Char | 1 | 14b Hospitalization |
| 17 | ie314c | Char | 1 | 14c Infectious episode |
| 18 | ie314d | Char | 1 | 14d Surgical intervention |
| 19 | ie316 | Char | 1 | 16 Event listed in NCIs CTCAE |
| 20 | ie316as | Char | 50 | 16a Specify short name of event |
| 21 | ie316at | Char | 50 | 16a Specify short name of event |
| 22 | ie317 | Char | 1 | 17 Severity grade |
| 23 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 24 | ie312 | Num | 8 | 12, Date event started (days since enrollment) |
| 25 | ie318 | Num | 8 | 18, Date event resolved (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|------|
| Data Set Name | OTP.IR | Observations | 2916 |
| Member Type | DATA | Variables | 66 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:12 | Observation Length | 512 |
| Last Modified | 03/10/2023 17:44:12 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 24 |
| First Data Page | 1 |
| Max Obs per Page | 127 |
| Obs in First Data Page | 109 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\ir.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 2MB |
| File Size (bytes) | 1638400 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ir108 | Char | 1 | 8 Upper abdominal ultrasound in past 6 mos/since last visit |
| 6 | ir110a | Char | 1 | 10a Fatty infiltration |
| 7 | ir110b | Char | 1 | 10b Cirrhosis |
| 8 | ir110c | Char | 1 | 10c Hepatomegaly |
| 9 | ir110d | Char | 1 | 10d Hepatic mass |
| 10 | ir110e | Char | 1 | 10e Intrahepatic biliary dilatation |
| 11 | ir110f | Char | 1 | 10f Extrahepatic biliary dilatation |
| 12 | ir110g | Char | 1 | 10g Gallstones/cholelithiasis |
| 13 | ir110h | Char | 1 | 10h Gall bladder polyps |
| 14 | ir110i | Char | 1 | 10i Cholecystectomy |
| 15 | ir110j | Char | 1 | 10j Splenomegaly |
| 16 | ir110k | Char | 1 | 10k Ascites |
| 17 | ir110l | Char | 1 | 10l Other features of portal hypertension |
| 18 | ir110ls | Char | 35 | 10l Specify features of portal hypertension |
| 19 | ir110lt | Char | 35 | 10l Specify features of portal hypertension |
| 20 | ir110m | Char | 1 | 10m Other abnormality |
| 21 | ir110ms | Char | 35 | 10m Specify other abnormality |
| 22 | ir110mt | Char | 35 | 10m Specify other abnormality |
| 23 | ir110n | Char | 1 | 10n None of the above |
| 24 | ir111 | Char | 1 | 11 Upper abdominal CT scan in past 6 mos/since last visit |
| 25 | ir113a | Char | 1 | 13a Fatty infiltration |
| 26 | ir113b | Char | 1 | 13b Cirrhosis |
| 27 | ir113c | Char | 1 | 13c Hepatomegaly |
| 28 | ir113d | Char | 1 | 13d Hepatic mass |
| 29 | ir113e | Char | 1 | 13e Hepatic hemangioma |
| 30 | ir113f | Char | 1 | 13f Hepatic cyst |
| 31 | ir113g | Char | 1 | 13g Intrahepatic biliary dilation |
| 32 | ir113h | Char | 1 | 13h Extrahepatic biliary dilation |
| 33 | ir113i | Char | 1 | 13i Gallstones/cholelithiasis |
| 34 | ir113j | Char | 1 | 13j Gall bladder polyps |
| 35 | ir113k | Char | 1 | 13k Cholecystectomy |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 36 | ir113l | Char | 1 | 13l Splenomegaly |
| 37 | ir113m | Char | 1 | 13m Ascites |
| 38 | ir113n | Char | 1 | 13n Other features of portal hypertension |
| 39 | ir113ns | Char | 35 | 13n Specify features of portal hypertension |
| 40 | ir113nt | Char | 35 | 13n Specify features of portal hypertension |
| 41 | ir113o | Char | 1 | 13o Other abnormality |
| 42 | ir113os | Char | 35 | 13o Specify other abnormality |
| 43 | ir113ot | Char | 35 | 13o Specify other abnormality |
| 44 | ir113p | Char | 1 | 13p None of the above |
| 45 | ir114 | Char | 1 | 14 Upper abdominal MRI in past 6 mos/since last visit |
| 46 | ir116a | Char | 1 | 16a Fatty infiltration |
| 47 | ir116b | Char | 1 | 16b Cirrhosis |
| 48 | ir116c | Char | 1 | 16c Hepatomegaly |
| 49 | ir116d | Char | 1 | 16d Hepatic mass |
| 50 | ir116e | Char | 1 | 16e Hepatic hemangioma |
| 51 | ir116f | Char | 1 | 16f Hepatic cyst |
| 52 | ir116g | Char | 1 | 16g Intrahepatic biliary dilation |
| 53 | ir116h | Char | 1 | 16h Extrahepatic biliary dilation |
| 54 | ir116i | Char | 1 | 16i Splenomegaly |
| 55 | ir116j | Char | 1 | 16j Ascites |
| 56 | ir116k | Char | 1 | 16k Other features of portal hypertension |
| 57 | ir116ks | Char | 35 | 16k Specify features of portal hypertension |
| 58 | ir116kt | Char | 35 | 16k Specify features of portal hypertension |
| 59 | ir116l | Char | 1 | 16l Other abnormality |
| 60 | ir116ls | Char | 35 | 16l Specify other abnormality |
| 61 | ir116lt | Char | 35 | 16l Specify other abnormality |
| 62 | ir116m | Char | 1 | 16m None of the above |
| 63 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 64 | ir109 | Num | 8 | 9, Date of most recent upper abdominal ultrasound (days since enrollment) |
| 65 | ir112 | Num | 8 | 12, Date of most recent upper abdominal CT scan (days since enrollment) |
| 66 | ir115 | Num | 8 | 15, Date of most recent upper abdominal MRI (days since enrollment) |

The CONTENTS Procedure

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|------|
| Data Set Name | OTP.LD | Observations | 1690 |
| Member Type | DATA | Variables | 186 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:13 | Observation Length | 344 |
| Last Modified | 03/10/2023 17:44:13 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 10 |
| First Data Page | 1 |
| Max Obs per Page | 190 |
| Obs in First Data Page | 123 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositores\limaccds\Dbase2\public_masterset\Datasets\Adults\ld.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 704KB |
| File Size (bytes) | 720896 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ld108 | Char | 1 | 8 Ever had at least one drink of alcohol... |
| 6 | ld109a | Char | 2 | 9a Age when began regular drinking: years |
| 7 | ld109b | Char | 2 | 9b Age when began regular drinking: months |
| 8 | ld110a | Char | 2 | 10a Age at end of first stage: years |
| 9 | ld110b | Char | 2 | 10b Age at end of first stage: months |
| 10 | ld111 | Char | 2 | 11 No. drinks on average per occasion |
| 11 | ld112 | Char | 2 | 12 No. days per month at this level |
| 12 | ld113 | Char | 2 | 13 Maximum number of drinks in one day |
| 13 | ld114a | Char | 3 | 14 Beer (%) |
| 14 | ld114b | Char | 3 | 14 Liquor (%) |
| 15 | ld114c | Char | 3 | 14 Wine (%) |
| 16 | ld115 | Char | 1 | 15 Usual style of drinking |
| 17 | ld116 | Char | 1 | 16 Events that altered usual drinking habits |
| 18 | ld117a | Char | 1 | 17a Marital/family |
| 19 | ld117b | Char | 1 | 17b Work |
| 20 | ld117c | Char | 1 | 17c School |
| 21 | ld117d | Char | 1 | 17d Medical |
| 22 | ld117e | Char | 1 | 17e Residence |
| 23 | ld117f | Char | 1 | 17f Legal/jail |
| 24 | ld117g | Char | 1 | 17g Financial |
| 25 | ld117h | Char | 1 | 17h Peer group |
| 26 | ld117i | Char | 1 | 17i Drug abuse |
| 27 | ld117j | Char | 1 | 17j Treatment |
| 28 | ld117k | Char | 1 | 17k Death |
| 29 | ld117l | Char | 1 | 17l Emotional |
| 30 | ld118a | Char | 3 | 18 Drink alone (%) |
| 31 | ld118b | Char | 3 | 18 Drink with others (%) |
| 32 | ld119a | Char | 3 | 19 Drink in the morning (%) |
| 33 | ld119b | Char | 3 | 19 Drink in the afternoon (%) |
| 34 | ld119c | Char | 3 | 19 Drink in the evening (%) |
| 35 | ld120 | Char | 1 | 20 Events in life changed drinking habits |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 36 | ld121a | Char | 2 | 21a Age at the beginning of phase: years |
| 37 | ld121b | Char | 2 | 21b Age at the beginning of phase: months |
| 38 | ld122a | Char | 2 | 22a Age at end of this phase: years |
| 39 | ld122b | Char | 2 | 22b Age at end of this phase: months |
| 40 | ld123 | Char | 2 | 23 No. drinks on average per occasion |
| 41 | ld124 | Char | 2 | 24 No. days per month at this level |
| 42 | ld125 | Char | 2 | 25 Maximum number of drinks in one day |
| 43 | ld126a | Char | 3 | 26 Beer (%) |
| 44 | ld126b | Char | 3 | 26 Liquor (%) |
| 45 | ld126c | Char | 3 | 26 Wine (%) |
| 46 | ld127 | Char | 1 | 27 Usual style of drinking |
| 47 | ld128 | Char | 1 | 28 Events that altered usual drinking habits |
| 48 | ld129a | Char | 1 | 29a Marital/family |
| 49 | ld129b | Char | 1 | 29b Work |
| 50 | ld129c | Char | 1 | 29c School |
| 51 | ld129d | Char | 1 | 29d Medical |
| 52 | ld129e | Char | 1 | 29e Residence |
| 53 | ld129f | Char | 1 | 29f Legal/jail |
| 54 | ld129g | Char | 1 | 29g Financial |
| 55 | ld129h | Char | 1 | 29h Peer group |
| 56 | ld129i | Char | 1 | 29i Drug abuse |
| 57 | ld129j | Char | 1 | 29j Treatment |
| 58 | ld129k | Char | 1 | 29k Death |
| 59 | ld129l | Char | 1 | 29l Emotional |
| 60 | ld130a | Char | 3 | 30 Drink alone (%) |
| 61 | ld130b | Char | 3 | 30 Drink with others (%) |
| 62 | ld131a | Char | 3 | 31 Drink in the morning (%) |
| 63 | ld131b | Char | 3 | 31 Drink in the afternoon (%) |
| 64 | ld131c | Char | 3 | 31 Drink in the evening (%) |
| 65 | ld132 | Char | 1 | 32 Events in life changed drinking habits |
| 66 | ld133a | Char | 2 | 33a Age at the beginning of phase: years |
| 67 | ld133b | Char | 2 | 33b Age at the beginning of phase: months |
| 68 | ld134a | Char | 2 | 34a Age at end of this phase: years |
| 69 | ld134b | Char | 2 | 34b Age at end of this phase: months |
| 70 | ld135 | Char | 2 | 35 No. drinks on average per occasion |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 71 | ld136 | Char | 2 | 36 No. days per month at this level |
| 72 | ld137 | Char | 2 | 37 Maximum number of drinks in one day |
| 73 | ld138a | Char | 3 | 38 Beer (%) |
| 74 | ld138b | Char | 3 | 38 Liquor (%) |
| 75 | ld138c | Char | 3 | 38 Wine (%) |
| 76 | ld139 | Char | 1 | 39 Usual style of drinking |
| 77 | ld140 | Char | 1 | 40 Events that altered usual drinking habits |
| 78 | ld141a | Char | 1 | 41a Marital/family |
| 79 | ld141b | Char | 1 | 41b Work |
| 80 | ld141c | Char | 1 | 41c School |
| 81 | ld141d | Char | 1 | 41d Medical |
| 82 | ld141e | Char | 1 | 41e Residence |
| 83 | ld141f | Char | 1 | 41f Legal/jail |
| 84 | ld141g | Char | 1 | 41g Financial |
| 85 | ld141h | Char | 1 | 41h Peer group |
| 86 | ld141i | Char | 1 | 41i Drug abuse |
| 87 | ld141j | Char | 1 | 41j Treatment |
| 88 | ld141k | Char | 1 | 41k Death |
| 89 | ld141l | Char | 1 | 41l Emotional |
| 90 | ld142a | Char | 3 | 42 Drink alone (%) |
| 91 | ld142b | Char | 3 | 42 Drink with others (%) |
| 92 | ld143a | Char | 3 | 43 Drink in the morning (%) |
| 93 | ld143b | Char | 3 | 43 Drink in the afternoon (%) |
| 94 | ld143c | Char | 3 | 43 Drink in the evening (%) |
| 95 | ld144 | Char | 1 | 44 Events that altered usual drinking habits |
| 96 | ld145a | Char | 2 | 45a Age at the beginning of phase: years |
| 97 | ld145b | Char | 2 | 45b Age at the beginning of phase: months |
| 98 | ld146a | Char | 2 | 46a Age at end of this phase: years |
| 99 | ld146b | Char | 2 | 46b Age at end of this phase: months |
| 100 | ld147 | Char | 2 | 47 No. drinks on average per occasion |
| 101 | ld148 | Char | 2 | 48 No. days per month at this level |
| 102 | ld149 | Char | 2 | 49 Maximum number of drinks in one day |
| 103 | ld150a | Char | 3 | 50 Beer (%) |
| 104 | ld150b | Char | 3 | 50 Liquor (%) |
| 105 | ld150c | Char | 3 | 50 Wine (%) |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 106 | ld151 | Char | 1 | 51 Usual style of drinking |
| 107 | ld152 | Char | 1 | 52 Events that altered usual drinking habits |
| 108 | ld153a | Char | 1 | 53a Marital/family |
| 109 | ld153b | Char | 1 | 53b Work |
| 110 | ld153c | Char | 1 | 53c School |
| 111 | ld153d | Char | 1 | 53d Medical |
| 112 | ld153e | Char | 1 | 53e Residence |
| 113 | ld153f | Char | 1 | 53f Legal/jail |
| 114 | ld153g | Char | 1 | 53g Financial |
| 115 | ld153h | Char | 1 | 53h Peer group |
| 116 | ld153i | Char | 1 | 53i Drug abuse |
| 117 | ld153j | Char | 1 | 53j Treatment |
| 118 | ld153k | Char | 1 | 53k Death |
| 119 | ld153l | Char | 1 | 53l Emotional |
| 120 | ld154a | Char | 3 | 54 Drink alone (%) |
| 121 | ld154b | Char | 3 | 54 Drink with others (%) |
| 122 | ld155a | Char | 3 | 55 Drink in the morning (%) |
| 123 | ld155b | Char | 3 | 55 Drink in the afternoon (%) |
| 124 | ld155c | Char | 3 | 55 Drink in the evening (%) |
| 125 | ld156 | Char | 1 | 56 Events that altered usual drinking habits |
| 126 | ld157a | Char | 2 | 57a Age at the beginning of phase: years |
| 127 | ld157b | Char | 2 | 57b Age at the beginning of phase: months |
| 128 | ld158a | Char | 2 | 58a Age at end of this phase: years |
| 129 | ld158b | Char | 2 | 58b Age at end of this phase: months |
| 130 | ld159 | Char | 2 | 59 No. drinks on average per occasion |
| 131 | ld160 | Char | 2 | 60 No. days per month at this level |
| 132 | ld161 | Char | 2 | 61 Maximum number of drinks in one day |
| 133 | ld162a | Char | 3 | 62 Beer (%) |
| 134 | ld162b | Char | 3 | 62 Liquor (%) |
| 135 | ld162c | Char | 3 | 62 Wine (%) |
| 136 | ld163 | Char | 1 | 63 Usual style of drinking |
| 137 | ld164 | Char | 1 | 64 Events that altered usual drinking habits |
| 138 | ld165a | Char | 1 | 65a Marital/family |
| 139 | ld165b | Char | 1 | 65b Work |
| 140 | ld165c | Char | 1 | 65c School |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 141 | ld165d | Char | 1 | 65d Medical |
| 142 | ld165e | Char | 1 | 65e Residence |
| 143 | ld165f | Char | 1 | 65f Legal/jail |
| 144 | ld165g | Char | 1 | 65g Financial |
| 145 | ld165h | Char | 1 | 65h Peer group |
| 146 | ld165i | Char | 1 | 65i Drug abuse |
| 147 | ld165j | Char | 1 | 65j Treatment |
| 148 | ld165k | Char | 1 | 65k Death |
| 149 | ld165l | Char | 1 | 65l Emotional |
| 150 | ld166a | Char | 3 | 66 Drink alone (%) |
| 151 | ld166b | Char | 3 | 66 Drink with others (%) |
| 152 | ld167a | Char | 3 | 67 Drink in the morning (%) |
| 153 | ld167b | Char | 3 | 67 Drink in the afternoon (%) |
| 154 | ld167c | Char | 3 | 67 Drink in the evening (%) |
| 155 | ld168 | Char | 1 | 68 Events that altered usual drinking habits |
| 156 | ld169a | Char | 2 | 69a Age at the beginning of phase: years |
| 157 | ld169b | Char | 2 | 69b Age at the beginning of phase: months |
| 158 | ld170a | Char | 2 | 70a Age at end of this phase: years |
| 159 | ld170b | Char | 2 | 70b Age at end of this phase: months |
| 160 | ld171 | Char | 2 | 71 No. drinks on average per occasion |
| 161 | ld172 | Char | 2 | 72 No. days per month at this level |
| 162 | ld173 | Char | 2 | 73 Maximum number of drinks in one day |
| 163 | ld174a | Char | 3 | 74 Beer (%) |
| 164 | ld174b | Char | 3 | 74 Liquor (%) |
| 165 | ld174c | Char | 3 | 74 Wine (%) |
| 166 | ld175 | Char | 1 | 75 Usual style of drinking |
| 167 | ld176 | Char | 1 | 76 Events that altered usual drinking habits |
| 168 | ld177a | Char | 1 | 77a Marital/family |
| 169 | ld177b | Char | 1 | 77b Work |
| 170 | ld177c | Char | 1 | 77c School |
| 171 | ld177d | Char | 1 | 77d Medical |
| 172 | ld177e | Char | 1 | 77e Residence |
| 173 | ld177f | Char | 1 | 77f Legal/jail |
| 174 | ld177g | Char | 1 | 77g Financial |
| 175 | ld177h | Char | 1 | 77h Peer group |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|-------------------------------------|
| # | Variable | Type | Len | Label |
| 176 | ld177i | Char | 1 | 77i Drug abuse |
| 177 | ld177j | Char | 1 | 77j Treatment |
| 178 | ld177k | Char | 1 | 77k Death |
| 179 | ld177l | Char | 1 | 77l Emotional |
| 180 | ld178a | Char | 3 | 78 Drink alone (%) |
| 181 | ld178b | Char | 3 | 78 Drink with others (%) |
| 182 | ld179a | Char | 3 | 79 Drink in the morning (%) |
| 183 | ld179b | Char | 3 | 79 Drink in the afternoon (%) |
| 184 | ld179c | Char | 3 | 79 Drink in the evening (%) |
| 185 | ld180 | Char | 1 | 80 Additional phases |
| 186 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.LR1 | Observations | 643 |
| Member Type | DATA | Variables | 41 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:14 | Observation Length | 312 |
| Last Modified | 03/10/2023 17:44:14 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 4 |
| First Data Page | 1 |
| Max Obs per Page | 209 |
| Obs in First Data Page | 189 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\lr1.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 320KB |
| File Size (bytes) | 327680 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | lr109 | Num | 8 | 9 Hemoglobin (g/dL) |
| 6 | lr110 | Num | 8 | 10 Hematocrit (%) |
| 7 | lr111 | Num | 8 | 11 Mean corpuscular volume (MCV) (fL) |
| 8 | lr112 | Num | 8 | 12 White blood cell count (WBC) (10 ³ cells/uL) |
| 9 | lr113 | Num | 8 | 13 Platelet count (cells/mm ³) |
| 10 | lr115 | Num | 8 | 15 Blood urea nitrogen (BUN) (mg/dL) |
| 11 | lr116 | Num | 8 | 16 Creatinine (mg/dL) |
| 12 | lr117 | Num | 8 | 17 Uric acid (mg/dL) |
| 13 | lr119 | Num | 8 | 19 HbA1c (%) |
| 14 | lr121 | Num | 8 | 21 Bilirubin (total) (mg/dL) |
| 15 | lr122 | Num | 8 | 22 Bilirubin (conjugated or direct) (mg/dL) |
| 16 | lr123 | Num | 8 | 23 Aspartate aminotransferase (AST) (U/L) |
| 17 | lr123a | Num | 8 | 23a AST upper limit of normal (U/L) |
| 18 | lr124 | Num | 8 | 24 Alanine aminotransferase (ALT) (U/L) |
| 19 | lr124a | Num | 8 | 24a ALT upper limit of normal (U/L) |
| 20 | lr125 | Num | 8 | 25 Alkaline phosphatase (U/L) |
| 21 | lr125a | Num | 8 | 25a Alkaline phosphatase ULN (U/L) |
| 22 | lr126 | Num | 8 | 26 Gamma glutamyl transferase (GGT) (U/L) |
| 23 | lr127 | Num | 8 | 27 Total protein (g/dL) |
| 24 | lr128 | Num | 8 | 28 Albumin (g/dL) |
| 25 | lr129 | Num | 8 | 29 Prothrombin time (PT) (sec) |
| 26 | lr130 | Num | 8 | 30 International normalized ratio (INR) |
| 27 | lr131 | Num | 8 | 31 Fasting for at least 8 hours |
| 28 | lr132a | Num | 8 | 32a Triglycerides (mg/dL) |
| 29 | lr132b | Num | 8 | 32b Total cholesterol (mg/dL) |
| 30 | lr132c | Num | 8 | 32c HDL cholesterol (mg/dL) |
| 31 | lr132d | Num | 8 | 32d LDL cholesterol (mg/dL) |
| 32 | lr133 | Num | 8 | 33 Fasting for at least 8 hours |
| 33 | lr134a | Num | 8 | 34a Serum glucose (mg/dL) |
| 34 | lr134b | Num | 8 | 34b Serum insulin (uU/mL) |
| 35 | formdate | Num | 8 | 4 Form date (days since enrollment) |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 36 | lr108 | Num | 8 | 8 Date of blood draw for CBC (days since enrollment) |
| 37 | lr114 | Num | 8 | 14 Date of blood draw for chemistries (days since enrollment) |
| 38 | lr118 | Num | 8 | 18 Date of blood draw for HbA1c (days since enrollment) |
| 39 | lr120 | Num | 8 | 20 Date of blood draw for liver panel (days since enrollment) |
| 40 | lr132 | Num | 8 | 32 Blood draw date for fasting lipid profile (days since enrollment) |
| 41 | lr134 | Num | 8 | 34 Blood draw date for fasting glucose and insulin (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.LR2 | Observations | 5150 |
| Member Type | DATA | Variables | 41 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:15 | Observation Length | 312 |
| Last Modified | 03/10/2023 17:44:15 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 25 |
| First Data Page | 1 |
| Max Obs per Page | 209 |
| Obs in First Data Page | 189 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\lr2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 2MB |
| File Size (bytes) | 1703936 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | lr109 | Num | 8 | 9 Hemoglobin (g/dL) |
| 6 | lr110 | Num | 8 | 10 Hematocrit (%) |
| 7 | lr111 | Num | 8 | 11 Mean corpuscular volume (MCV) (fL) |
| 8 | lr112 | Num | 8 | 12 White blood cell count (WBC) (10 ³ cells/uL) |
| 9 | lr213 | Num | 8 | 13 Platelet count (cells/mm ³) |
| 10 | lr215 | Num | 8 | 15 Blood urea nitrogen (BUN) (mg/dL) |
| 11 | lr216 | Num | 8 | 16 Creatinine (mg/dL) |
| 12 | lr217 | Num | 8 | 17 Uric acid (mg/dL) |
| 13 | lr219 | Num | 8 | 19 HbA1c (%) |
| 14 | lr221 | Num | 8 | 21 Bilirubin (total) (mg/dL) |
| 15 | lr222 | Num | 8 | 22 Bilirubin (conjugated or direct) (mg/dL) |
| 16 | lr223 | Num | 8 | 23 Aspartate aminotransferase (AST) (U/L) |
| 17 | lr223a | Num | 8 | 23a AST upper limit of normal (U/L) |
| 18 | lr224 | Num | 8 | 24 Alanine aminotransferase (ALT) (U/L) |
| 19 | lr224a | Num | 8 | 24a ALT upper limit of normal (U/L) |
| 20 | lr225 | Num | 8 | 25 Alkaline phosphatase (U/L) |
| 21 | lr225a | Num | 8 | 25a Alkaline phosphatase ULN (U/L) |
| 22 | lr226 | Num | 8 | 26 Gamma glutamyl transferase (GGT) (U/L) |
| 23 | lr227 | Num | 8 | 27 Total protein (g/dL) |
| 24 | lr228 | Num | 8 | 28 Albumin (g/dL) |
| 25 | lr229 | Num | 8 | 29 Prothrombin time (PT) (sec) |
| 26 | lr230 | Num | 8 | 30 International normalized ratio (INR) |
| 27 | lr231 | Num | 8 | 31 Fasting for at least 8 hours |
| 28 | lr232a | Num | 8 | 32a Triglycerides (mg/dL) |
| 29 | lr232b | Num | 8 | 32b Total cholesterol (mg/dL) |
| 30 | lr232c | Num | 8 | 32c HDL cholesterol (mg/dL) |
| 31 | lr232d | Num | 8 | 32d LDL cholesterol (mg/dL) |
| 32 | lr233 | Num | 8 | 33 Fasting for at least 8 hours |
| 33 | lr234a | Num | 8 | 34a Serum glucose (mg/dL) |
| 34 | lr234b | Num | 8 | 34b Serum insulin (uU/mL) |
| 35 | formdate | Num | 8 | 4 Form date (days since enrollment) |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 36 | lr208 | Num | 8 | 8 Date of blood draw for CBC (days since enrollment) |
| 37 | lr214 | Num | 8 | 14 Date of blood draw for chemistries (days since enrollment) |
| 38 | lr218 | Num | 8 | 18 Date of blood draw for HbA1c (days since enrollment) |
| 39 | lr220 | Num | 8 | 20 Date of blood draw for liver panel (days since enrollment) |
| 40 | lr232 | Num | 8 | 32 Blood draw date for fasting lipid profile (days since enrollment) |
| 41 | lr234 | Num | 8 | 34 Blood draw date for fasting glucose and insulin (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.LR3 | Observations | 3839 |
| Member Type | DATA | Variables | 42 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:17 | Observation Length | 320 |
| Last Modified | 03/10/2023 17:44:17 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 19 |
| First Data Page | 1 |
| Max Obs per Page | 204 |
| Obs in First Data Page | 184 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\lr3.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 1MB |
| File Size (bytes) | 1310720 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | lr309 | Num | 8 | 9 Hemoglobin (g/dL) |
| 6 | lr310 | Num | 8 | 10 Hematocrit (%) |
| 7 | lr311 | Num | 8 | 11 Mean corpuscular volume (MCV) (fL) |
| 8 | lr312a | Num | 8 | 12a White blood cell count (WBC) (10 ³ cells/uL) |
| 9 | lr312b | Num | 8 | 12b Red blood cell count (RBC) (cells/mcL) |
| 10 | lr313 | Num | 8 | 13 Platelet count (cells/mm ³) |
| 11 | lr315 | Num | 8 | 15 Blood urea nitrogen (BUN) (mg/dL) |
| 12 | lr316 | Num | 8 | 16 Creatinine (mg/dL) |
| 13 | lr317 | Num | 8 | 17 Uric acid (mg/dL) |
| 14 | lr319 | Num | 8 | 19 HbA1c (%) |
| 15 | lr321 | Num | 8 | 21 Bilirubin (total) (mg/dL) |
| 16 | lr322 | Num | 8 | 22 Bilirubin (conjugated or direct) (mg/dL) |
| 17 | lr323 | Num | 8 | 23 Aspartate aminotransferase (AST) (U/L) |
| 18 | lr323a | Num | 8 | 23a AST upper limit of normal (U/L) |
| 19 | lr324 | Num | 8 | 24 Alanine aminotransferase (ALT) (U/L) |
| 20 | lr324a | Num | 8 | 24a ALT upper limit of normal (U/L) |
| 21 | lr325 | Num | 8 | 25 Alkaline phosphatase (U/L) |
| 22 | lr325a | Num | 8 | 25a Alkaline phosphatase ULN (U/L) |
| 23 | lr326 | Num | 8 | 26 Gamma glutamyl transferase (GGT) (U/L) |
| 24 | lr327 | Num | 8 | 27 Total protein (g/dL) |
| 25 | lr328 | Num | 8 | 28 Albumin (g/dL) |
| 26 | lr329 | Num | 8 | 29 Prothrombin time (PT) (sec) |
| 27 | lr330 | Num | 8 | 30 International normalized ratio (INR) |
| 28 | lr331 | Num | 8 | 31 Fasting for at least 8 hours |
| 29 | lr332a | Num | 8 | 32a Triglycerides (mg/dL) |
| 30 | lr332b | Num | 8 | 32b Total cholesterol (mg/dL) |
| 31 | lr332c | Num | 8 | 32c HDL cholesterol (mg/dL) |
| 32 | lr332d | Num | 8 | 32d LDL cholesterol (mg/dL) |
| 33 | lr333 | Num | 8 | 33 Fasting for at least 8 hours |
| 34 | lr334a | Num | 8 | 34a Serum glucose (mg/dL) |
| 35 | lr334b | Num | 8 | 34b Serum insulin (uU/mL) |

Dataset: LR3 - Laboratory Results - Screening and Follow-up, revision 3**The CONTENTS Procedure**

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 36 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 37 | lr308 | Num | 8 | 8 Date of blood draw for CBC (days since enrollment) |
| 38 | lr314 | Num | 8 | 14 Date of blood draw for chemistries (days since enrollment) |
| 39 | lr318 | Num | 8 | 18 Date of blood draw for HbA1c (days since enrollment) |
| 40 | lr320 | Num | 8 | 20 Date of blood draw for liver panel (days since enrollment) |
| 41 | lr332 | Num | 8 | 32 Blood draw date for fasting lipid profile (days since enrollment) |
| 42 | lr334 | Num | 8 | 34 Blood draw date for fasting glucose and insulin (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

Dataset: LS1 - Laboratory Results - Tests Done Only During Screening, revision 1

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|------|
| Data Set Name | OTP.LS1 | Observations | 1635 |
| Member Type | DATA | Variables | 61 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:18 | Observation Length | 312 |
| Last Modified | 03/10/2023 17:44:18 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 8 |
| First Data Page | 1 |
| Max Obs per Page | 209 |
| Obs in First Data Page | 181 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\ls1.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 576KB |
| File Size (bytes) | 589824 |

Dataset: LS1 - Laboratory Results - Tests Done Only During Screening, revision 1

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ls108 | Char | 1 | 8 Continuing from DB, PIVENS, or TONIC |
| 6 | ls109 | Char | 1 | 9 New labs available from continuing patient |
| 7 | ls110a | Char | 1 | 10a Hepatitis B surface antigen |
| 8 | ls110b | Char | 1 | 10b Hepatitis B core total antibody |
| 9 | ls110c | Char | 1 | 10c Hepatitis B surface antibody |
| 10 | ls110d | Char | 1 | 10d Hepatitis C antibody |
| 11 | ls110e | Char | 1 | 10e Hepatitis C virus RNA |
| 12 | ls110f | Char | 1 | 10f Hepatitis A virus antibody |
| 13 | ls111a | Num | 8 | 11a Iron (ug/dL) |
| 14 | ls111b | Num | 8 | 11b Total iron binding capacity (ug/dL) |
| 15 | ls111c | Num | 8 | 11c Ferritin (ng/ml) |
| 16 | ls112 | Char | 1 | 12 Hepatic iron index available |
| 17 | ls113 | Num | 8 | 13 Hepatic iron index (umol/g/year) |
| 18 | ls114 | Char | 1 | 14 Abnormality in iron overload |
| 19 | ls116 | Char | 1 | 16 Type of abnormality |
| 20 | ls117 | Char | 1 | 17 Patient 40 years or younger |
| 21 | ls119 | Num | 8 | 19 Ceruloplasmin (mg/dL) |
| 22 | ls119a | Num | 8 | 19a Ceruloplasmin ULN (mg/dL) |
| 23 | ls119b | Num | 8 | 19b Ceruloplasmin LLN (mg/dL) |
| 24 | ls121 | Num | 8 | 21 Alpha-1 antitrypsin concentration (mg/dL) |
| 25 | ls121a | Num | 8 | 21a AIAT ULN (mg/dL) |
| 26 | ls121b | Num | 8 | 21b AIAT LLN (mg/dL) |
| 27 | ls122a | Char | 1 | 22a Pi Z heterozygote |
| 28 | ls122b | Char | 1 | 22b Pi ZZ homozygote |
| 29 | ls123 | Char | 1 | 23 AIAT deficiency contributing to liver dx |
| 30 | ls125 | Char | 1 | 25 Antinuclear antibody (ANA) |
| 31 | ls125a | Num | 8 | 25a ANA titer |
| 32 | ls125b | Num | 8 | 25b ANA units |
| 33 | ls126 | Char | 1 | 26 Antismooth muscle antibody (ASMA) |
| 34 | ls126a | Num | 8 | 26a ASMA titer |
| 35 | ls126b | Num | 8 | 26b ASMA units |

Dataset: LS1 - Laboratory Results - Tests Done Only During Screening, revision 1

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 36 | Is127 | Char | 1 | 27 Antimitochondrial antibody (AMA) |
| 37 | Is127a | Num | 8 | 27a AMA titer |
| 38 | Is127b | Num | 8 | 27b AMA units |
| 39 | Is128 | Char | 1 | Patient 18 or older |
| 40 | Is129 | Char | 1 | 29 Lymphocytotoxic antibody (LCA) |
| 41 | Is129a | Num | 8 | 29a LCA titer |
| 42 | Is129b | Num | 8 | 29b LCA units |
| 43 | Is130 | Char | 1 | 30 Liver-kidney microsomal antigen (LKM1) |
| 44 | Is130a | Num | 8 | 30a LKM1 titer |
| 45 | Is130b | Num | 8 | 30b LKM1 units |
| 46 | Is131 | Char | 1 | 31 Rheumatoid factor (RF) |
| 47 | Is131a | Num | 8 | 31a RF units |
| 48 | Is132 | Char | 1 | 32 Immunoglobulin levels available |
| 49 | Is134 | Num | 8 | 34 IgA |
| 50 | Is135 | Num | 8 | 35 IgG |
| 51 | Is136 | Num | 8 | 36 IgM |
| 52 | Is138 | Num | 8 | 38 Thyroid stimulating hormone (TSH) |
| 53 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 54 | Is110 | Num | 8 | 10 Date of blood draw for serological assays (days since enrollment) |
| 55 | Is111 | Num | 8 | 11 Date of blood draw for iron overload screening (days since enrollment) |
| 56 | Is115 | Num | 8 | 15 Date of blood draw for HFE gene analysis (days since enrollment) |
| 57 | Is118 | Num | 8 | 18 Date of blood draw for ceruloplasmin (days since enrollment) |
| 58 | Is120 | Num | 8 | 20 Date of blood draw for alpha-1 antitrypsin (days since enrollment) |
| 59 | Is124 | Num | 8 | 24 Date of blood draw for autoantibody tests (days since enrollment) |
| 60 | Is133 | Num | 8 | 33 Date of blood draw for immunoglobulin levels (days since enrollment) |
| 61 | Is137 | Num | 8 | 37 Date of blood draw for thyroid stimulating hormone (TSH) (days since enrollment) |

| Sort Information | |
|------------------|----------|
| Sortedby | id visit |
| Validated | YES |
| Character Set | ANSI |

Dataset: LS2 - Laboratory Results - Tests Done Only During Screening, revision 2

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|-----|
| Data Set Name | OTP.LS2 | Observations | 380 |
| Member Type | DATA | Variables | 62 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:19 | Observation Length | 312 |
| Last Modified | 03/10/2023 17:44:19 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 2 |
| First Data Page | 1 |
| Max Obs per Page | 209 |
| Obs in First Data Page | 181 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_masterset\Datasets\Adults\ls2.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 192KB |
| File Size (bytes) | 196608 |

Dataset: LS2 - Laboratory Results - Tests Done Only During Screening, revision 2

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|--|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | ls208 | Char | 1 | 8 Continuing from DB, PIVENS, or TONIC |
| 6 | ls209 | Char | 1 | 9 New labs available from continuing patient |
| 7 | ls210a | Char | 1 | 10a Hepatitis B surface antigen |
| 8 | ls210b | Char | 1 | 10b Hepatitis B core total antibody |
| 9 | ls210c | Char | 1 | 10c Hepatitis B surface antibody |
| 10 | ls210d | Char | 1 | 10d Hepatitis C antibody |
| 11 | ls210e | Char | 1 | 10e Hepatitis C virus RNA |
| 12 | ls210f | Char | 1 | 10f Hepatitis A virus antibody |
| 13 | ls211a | Num | 8 | 11a Iron (ug/dL) |
| 14 | ls211b | Num | 8 | 11b Total iron binding capacity (ug/dL) |
| 15 | ls211c | Num | 8 | 11c Ferritin (ng/ml) |
| 16 | ls212 | Char | 1 | 12 Hepatic iron index available |
| 17 | ls213 | Num | 8 | 13 Hepatic iron index (umol/g/year) |
| 18 | ls214 | Char | 1 | 14 Abnormality in iron overload |
| 19 | ls216 | Char | 1 | 16 Type of abnormality |
| 20 | ls217 | Char | 1 | 17 Patient 40 years or younger |
| 21 | ls217a | Char | 1 | 17a Ceruloplasmin value available |
| 22 | ls219 | Num | 8 | 19 Ceruloplasmin (mg/dL) |
| 23 | ls219a | Num | 8 | 19a Ceruloplasmin ULN (mg/dL) |
| 24 | ls219b | Num | 8 | 19b Ceruloplasmin LLN (mg/dL) |
| 25 | ls221 | Num | 8 | 21 Alpha-1 antitrypsin concentration (mg/dL) |
| 26 | ls221a | Num | 8 | 21a AIAT ULN (mg/dL) |
| 27 | ls221b | Num | 8 | 21b AIAT LLN (mg/dL) |
| 28 | ls222a | Char | 1 | 22a Pi Z heterozygote |
| 29 | ls222b | Char | 1 | 22b Pi ZZ homozygote |
| 30 | ls223 | Char | 1 | 23 AIAT deficiency contributing to liver dx |
| 31 | ls225 | Char | 1 | 25 Antinuclear antibody (ANA) |
| 32 | ls225a | Num | 8 | 25a ANA titer |
| 33 | ls225b | Num | 8 | 25b ANA units |
| 34 | ls226 | Char | 1 | 26 Antismooth muscle antibody (ASMA) |
| 35 | ls226a | Num | 8 | 26a ASMA titer |

Dataset: LS2 - Laboratory Results - Tests Done Only During Screening, revision 2

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 36 | ls226b | Num | 8 | 26b ASMA units |
| 37 | ls227 | Char | 1 | 27 Antimitochondrial antibody (AMA) |
| 38 | ls227a | Num | 8 | 27a AMA titer |
| 39 | ls227b | Num | 8 | 27b AMA units |
| 40 | ls228 | Char | 1 | Patient 18 or older |
| 41 | ls229 | Char | 1 | 29 Lymphocytotoxic antibody (LCA) |
| 42 | ls229a | Num | 8 | 29a LCA titer |
| 43 | ls229b | Num | 8 | 29b LCA units |
| 44 | ls230 | Char | 1 | 30 Liver-kidney microsomal antigen (LKM1) |
| 45 | ls230a | Num | 8 | 30a LKM1 titer |
| 46 | ls230b | Num | 8 | 30b LKM1 units |
| 47 | ls231 | Char | 1 | 31 Rheumatoid factor (RF) |
| 48 | ls231a | Num | 8 | 31a RF units |
| 49 | ls232 | Char | 1 | 32 Immunoglobulin levels available |
| 50 | ls234 | Num | 8 | 34 IgA |
| 51 | ls235 | Num | 8 | 35 IgG |
| 52 | ls236 | Num | 8 | 36 IgM |
| 53 | ls238 | Num | 8 | 38 Thyroid stimulating hormone (TSH) |
| 54 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 55 | ls210 | Num | 8 | 10 Date of blood draw for serological assays (days since enrollment) |
| 56 | ls211 | Num | 8 | 11 Date of blood draw for iron overload screening (days since enrollment) |
| 57 | ls215 | Num | 8 | 15 Date of blood draw for HFE gene analysis (days since enrollment) |
| 58 | ls218 | Num | 8 | 18 Date of blood draw for ceruloplasmin (days since enrollment) |
| 59 | ls220 | Num | 8 | 20 Date of blood draw for alpha-1 antitrypsin (days since enrollment) |
| 60 | ls224 | Num | 8 | 24 Date of blood draw for autoantibody tests (days since enrollment) |
| 61 | ls233 | Num | 8 | 33 Date of blood draw for immunoglobulin levels (days since enrollment) |
| 62 | ls237 | Num | 8 | 37 Date of blood draw for thyroid stimulating hormone (TSH) (days since enrollment) |

| Sort Information | |
|------------------|----------|
| Sortedby | id visit |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|-----|
| Data Set Name | OTP.LS3 | Observations | 310 |
| Member Type | DATA | Variables | 61 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:20 | Observation Length | 312 |
| Last Modified | 03/10/2023 17:44:20 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|---|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 2 |
| First Data Page | 1 |
| Max Obs per Page | 209 |
| Obs in First Data Page | 181 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\lbase2\public_master\Dataset\Adults\ls3.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 192KB |
| File Size (bytes) | 196608 |

| Alphabetic List of Variables and Attributes | | | | |
|---|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 3 | form | Char | 4 | 6 Form/revision |
| 53 | formdate | Num | 8 | 4 Form date (days since enrollment) |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 5 | ls308 | Char | 1 | 8 Continuing from DB, PIVENS, or TONIC |
| 6 | ls309 | Char | 1 | 9 New labs available from continuing patient |
| 54 | ls310 | Num | 8 | 10 Date of blood draw for serological assays (days since enrollment) |
| 55 | ls311 | Num | 8 | 11 Date of blood draw for iron overload screening (days since enrollment) |
| 16 | ls312 | Char | 1 | 12 Hepatic iron index available |
| 17 | ls313 | Num | 8 | 13 Hepatic iron index (umol/g/year) |

Dataset: LS3 - Laboratory Results - Tests Done Only During Screening, revision 3

The CONTENTS Procedure

| Alphabetic List of Variables and Attributes | | | | |
|---|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 18 | Is314 | Char | 1 | 14 Abnormality in iron overload |
| 56 | Is315 | Num | 8 | 15 Date of blood draw for HFE gene analysis (days since enrollment) |
| 19 | Is316 | Char | 1 | 16 Type of abnormality |
| 20 | Is317 | Char | 1 | 17 Patient 40 years or younger |
| 57 | Is318 | Num | 8 | 18 Date of blood draw for ceruloplasmin (days since enrollment) |
| 22 | Is319 | Num | 8 | 19 Ceruloplasmin (mg/dL) |
| 58 | Is320 | Num | 8 | 20 Date of blood draw for alpha-1 antitrypsin (days since enrollment) |
| 25 | Is321 | Num | 8 | 21 Alpha-1 antitrypsin concentration (mg/dL) |
| 28 | Is322 | Char | 1 | 22 A1AT phenotype |
| 29 | Is323 | Char | 1 | 23 AIAT deficiency contributing to liver dx |
| 59 | Is324 | Num | 8 | 24 Date of blood draw for autoantibody tests (days since enrollment) |
| 30 | Is325 | Char | 1 | 25 Antinuclear antibody (ANA) |
| 33 | Is326 | Char | 1 | 26 Antismooth muscle antibody (ASMA) |
| 36 | Is327 | Char | 1 | 27 Antimitochondrial antibody (AMA) |
| 39 | Is328 | Char | 1 | Patient 18 or older |
| 40 | Is329 | Char | 1 | 29 Lymphocytotoxic antibody (LCA) |
| 43 | Is330 | Char | 1 | 30 Liver-kidney microsomal antigen (LKM1) |
| 46 | Is331 | Char | 1 | 31 Rheumatoid factor (RF) |
| 48 | Is332 | Char | 1 | 32 Immunoglobulin levels available |
| 60 | Is333 | Num | 8 | 33 Date of blood draw for immunoglobulin levels (days since enrollment) |
| 49 | Is334 | Num | 8 | 34 IgA |
| 50 | Is335 | Num | 8 | 35 IgG |
| 51 | Is336 | Num | 8 | 36 IgM |
| 61 | Is337 | Num | 8 | 37 Date of blood draw for thyroid stimulating hormone (TSH) (days since enrollment) |
| 52 | Is338 | Num | 8 | 38 Thyroid stimulating hormone (TSH) |
| 7 | Is310a | Char | 1 | 10a Hepatitis B surface antigen |
| 8 | Is310b | Char | 1 | 10b Hepatitis B core total antibody |
| 9 | Is310c | Char | 1 | 10c Hepatitis B surface antibody |
| 10 | Is310d | Char | 1 | 10d Hepatitis C antibody |
| 11 | Is310e | Char | 1 | 10e Hepatitis C virus RNA |
| 12 | Is310f | Char | 1 | 10f Hepatitis A virus antibody |
| 13 | Is311a | Num | 8 | 11a Iron (ug/dL) |
| 14 | Is311b | Num | 8 | 11b Total iron binding capacity (ug/dL) |
| 15 | Is311c | Num | 8 | 11c Ferritin (ng/ml) |
| 21 | Is317a | Char | 1 | 17a Ceruloplasmin value available |

Dataset: LS3 - Laboratory Results - Tests Done Only During Screening, revision 3

The CONTENTS Procedure

| Alphabetic List of Variables and Attributes | | | | |
|---|----------|------|-----|-------------------------------|
| # | Variable | Type | Len | Label |
| 23 | ls319a | Num | 8 | 19a Ceruloplasmin ULN (mg/dL) |
| 24 | ls319b | Num | 8 | 19b Ceruloplasmin LLN (mg/dL) |
| 26 | ls321a | Num | 8 | 21a AIAT ULN (mg/dL) |
| 27 | ls321b | Num | 8 | 21b AIAT LLN (mg/dL) |
| 31 | ls325a | Num | 8 | 25a ANA titer |
| 32 | ls325b | Num | 8 | 25b ANA units |
| 34 | ls326a | Num | 8 | 26a ASMA titer |
| 35 | ls326b | Num | 8 | 26b ASMA units |
| 37 | ls327a | Num | 8 | 27a AMA titer |
| 38 | ls327b | Num | 8 | 27b AMA units |
| 41 | ls329a | Num | 8 | 29a LCA titer |
| 42 | ls329b | Num | 8 | 29b LCA units |
| 44 | ls330a | Num | 8 | 30a LKM1 titer |
| 45 | ls330b | Num | 8 | 30b LKM1 units |
| 47 | ls331a | Num | 8 | 31a RF units |
| 4 | study | Char | 1 | 7 Study |
| 2 | visit | Char | 4 | 5 Visit ID code |

| Sort Information | |
|------------------|----------|
| Sortedby | id visit |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|----------------------------|---------------------------|-----------------------------|------|
| Data Set Name | OTP.PE | Observations | 9421 |
| Member Type | DATA | Variables | 54 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:22 | Observation Length | 248 |
| Last Modified | 03/10/2023 17:44:22 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 36 |
| First Data Page | 1 |
| Max Obs per Page | 264 |
| Obs in First Data Page | 233 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\pe.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 2MB |
| File Size (bytes) | 2424832 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | pe108a | Num | 8 | 8a Height (1st measurement) |
| 6 | pe108b | Num | 8 | 8b Height (2nd measurement) |
| 7 | pe108c | Num | 8 | 8c Units of height measurement |
| 8 | pe109a | Num | 8 | 9a Weight (1st measurement) |
| 9 | pe109b | Num | 8 | 9b Weight (2nd measurement) |
| 10 | pe109c | Num | 8 | 9c Units of weight measurement |
| 11 | pe110a | Num | 8 | 10a Waist circumference (1st measurement) |
| 12 | pe110b | Num | 8 | 10b Waist circumference (2nd measurement) |
| 13 | pe110c | Num | 8 | 10c Units for waist measurement |
| 14 | pe111a | Num | 8 | 11a Hip circumference (1st measurement) |
| 15 | pe111b | Num | 8 | 11b Hip circumference (2nd measurement) |
| 16 | pe111c | Num | 8 | 11c Units for hip measurement |
| 17 | pe112a | Num | 8 | 12a Temperature (degrees) |
| 18 | pe112b | Num | 8 | 12b Scale for temperature |
| 19 | pe113a | Num | 8 | 13a Systolic BP (mmHg) |
| 20 | pe113b | Num | 8 | 13b Diastolic BP (mmHg) |
| 21 | pe114 | Num | 8 | 14 Resting radial pulse (beats/min) |
| 22 | pe115 | Num | 8 | 15 Respiratory rate (breaths/min) |
| 23 | pe116a | Char | 1 | 16a No acanthosis nigricans |
| 24 | pe116b | Char | 1 | 16b Acanthosis nigricans-neck |
| 25 | pe116c | Char | 1 | 16c Acanthosis nigricans-axilla |
| 26 | pe116d | Char | 1 | 16d Acanthosis nigricans-elbows |
| 27 | pe116e | Char | 1 | 16e Acanthosis nigricans-elbows |
| 28 | pe116f | Char | 1 | 16f Acanthosis nigricans-knuckles |
| 29 | pe116g | Char | 1 | 16g Acanthosis nigricans-periumbilical |
| 30 | pe117s | Char | 1 | 17a No abdomen abnormalities |
| 31 | pe117b | Char | 1 | 17b Ascites |
| 32 | pe117c | Char | 1 | 17c Obese |
| 33 | pe117d | Char | 1 | 17d Splenomegaly |
| 34 | pe17e | Char | 1 | 17e Hepatomegaly |
| 35 | pe117es | Num | 8 | 17e Hepatomegaly span (cm) |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|-------------------------------------|
| # | Variable | Type | Len | Label |
| 36 | pe118a | Char | 1 | 18a No liver signs |
| 37 | pe118b | Char | 1 | 18b Jaundice |
| 38 | pe118c | Char | 1 | 18c Palmar erythema |
| 39 | pe118d | Char | 1 | 18d Contractures |
| 40 | pe118e | Char | 1 | 18e Pedal edema |
| 41 | pe118f | Char | 1 | 18f Spider angiomas |
| 42 | pe118g | Char | 1 | 18g Asterixis |
| 43 | pe118h | Char | 1 | 18h Hepatic encephalopathy |
| 44 | pe118i | Char | 1 | 18i Other liver signs |
| 45 | pe118is | Char | 35 | 18is Specify liver signs |
| 46 | pe119 | Char | 1 | 19 Tanner staging required |
| 47 | pe120 | Char | 1 | 20 Is patient female |
| 48 | pe121 | Char | 1 | 21 Male genital stage |
| 49 | pe122 | Char | 1 | 22 Male pubic hair stage |
| 50 | pe123 | Char | 1 | 23 Female breast stage |
| 51 | pe124 | Char | 1 | 24 Female pubic hair stage |
| 52 | pe125 | Char | 1 | 25 Has menarche occurred |
| 53 | pe126 | Num | 8 | 26 Age at menarche |
| 54 | formdate | Num | 8 | 4 Form date (days since enrollment) |

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |

The CONTENTS Procedure

| | | | |
|---------------------|---------------------------|----------------------|------|
| Data Set Name | OTP.RG | Observations | 2325 |
| Member Type | DATA | Variables | 33 |
| Engine | V9 | Indexes | 0 |
| Created | 03/10/2023 17:44:22 | Observation Length | 200 |
| Last Modified | 03/10/2023 17:44:22 | Deleted Observations | 0 |
| Protection | | Compressed | NO |
| Data Set Type | | Sorted | YES |
| Label | | | |
| Data Representation | WINDOWS_64 | | |
| Encoding | wlatin1 Western (Windows) | | |

| Engine/Host Dependent Information | |
|-----------------------------------|--|
| Data Set Page Size | 65536 |
| Number of Data Set Pages | 8 |
| First Data Page | 1 |
| Max Obs per Page | 327 |
| Obs in First Data Page | 302 |
| Number of Data Set Repairs | 0 |
| ExtendObsCounter | YES |
| Filename | P:\Shared\Doc\NASH\Repositories\limaccds\Dbase2\public_masterset\Datasets\Adults\rg.sas7bdat |
| Release Created | 9.0401M5 |
| Host Created | X64_10PRO |
| Owner Name | . |
| File Size | 576KB |
| File Size (bytes) | 589824 |

The CONTENTS Procedure

| Variables in Creation Order | | | | |
|-----------------------------|----------|------|-----|---------------------------------------|
| # | Variable | Type | Len | Label |
| 1 | id | Char | 4 | Limited Use Dataset ID number |
| 2 | visit | Char | 4 | 5 Visit ID code |
| 3 | form | Char | 4 | 6 Form/revision |
| 4 | study | Char | 1 | 7 Study |
| 5 | rg108 | Char | 1 | 8 Signed informed consent |
| 6 | rg110 | Char | 2 | 10 Age at last birthday |
| 7 | rg111 | Char | 1 | 11 Gender |
| 8 | rg112 | Char | 1 | 12 Ethnic category |
| 9 | rg113 | Char | 1 | 13 Hispanic origin |
| 10 | rg113s | Char | 35 | 13 Specify other Spanish culture |
| 11 | rg114a | Char | 1 | 14a American Indian/Alaska Native |
| 12 | rg114b | Char | 1 | 14b Asian |
| 13 | rg114c | Char | 1 | 14c Black/African American |
| 14 | rg114d | Char | 1 | 14d Native Hawaiian/Pacific Islander |
| 15 | rg114e | Char | 1 | 14e White |
| 16 | rg114f | Char | 1 | 14f Refused |
| 17 | rg115 | Char | 1 | 15 Country of birth |
| 18 | rg115s | Char | 35 | 15 Specify other country |
| 19 | rg116 | Char | 1 | 16 Highest educational level |
| 20 | rg117 | Char | 1 | 17 Currently employed |
| 21 | rg119 | Char | 2 | 19 Hours/week work each week |
| 22 | rg120 | Char | 1 | 20 Occupational history category |
| 23 | rg120s | Char | 35 | 20 Specify other category |
| 24 | rg121 | Char | 1 | 21 Marital status |
| 25 | rg122 | Char | 1 | 22 Annual household income |
| 26 | rg123 | Char | 1 | 23 NASH ID previously assigned |
| 27 | rg124a | Char | 1 | 24a Database |
| 28 | rg124b | Char | 1 | 24b PIVENS |
| 29 | rg124c | Char | 1 | 24c TONIC |
| 30 | rg124d | Char | 1 | 24d Other NASH study |
| 31 | rg124ds | Char | 35 | 24d Specify other study |
| 32 | formdate | Num | 8 | 4 Form date (days before enrollment) |
| 33 | rg109 | Num | 8 | 9 Birth date (days before enrollment) |

The CONTENTS Procedure

| Sort Information | |
|------------------|------|
| Sortedby | id |
| Validated | YES |
| Character Set | ANSI |